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Ragadeepthi Tunduguru 
Regulation of skeletal muscle insulin sensitivity by PAK1 
Insulin-stimulated glucose uptake into skeletal muscle cells requires translocation 
of the glucose transporter-4 (GLUT4) from the cell interior to the plasma 
membrane. Insulin-stimulated GLUT4 vesicle translocation is dysregulated in 
Type 2 diabetes (T2D). The Group I p21–activated kinase (PAK1) is a required 
element in insulin-stimulated GLUT4 vesicle translocation in mouse skeletal 
muscle in vivo, although its placement and function(s) in the canonical insulin 
signaling cascade in skeletal muscle cells, remain undetermined. Therefore, the 
objective of my project is to determine the molecular mechanism(s) underlying 
the requirement for PAK1 in the process of insulin-stimulated GLUT4 vesicle 
translocation and subsequent glucose uptake by skeletal muscle cells.  
Toward this, my studies demonstrate that the pharmacological inhibition of PAK1 
activation blunts insulin-stimulated GLUT4 translocation and subsequent glucose 
uptake into L6-GLUT4myc skeletal myotubes. Inhibition of PAK1 activation also 
ablates insulin-stimulated F-actin cytoskeletal remodeling, a process known to be 
required for mobilizing GLUT4 vesicles to the plasma membrane. Consistent with 
this mechanism, PAK1 activation was also required for the activation of cofilin, 
another protein implicated in F-actin remodeling. Interestingly, my studies reveal 
a novel molecular mechanism involving PAK1 signaling to p41-ARC, a regulatory 
subunit of the cytoskeletal Arp2/3 complex, and its interactions with another 
cytoskeletal factor, N-WASP, to elicit the insulin-stimulated F-actin remodeling in 
skeletal muscle cells. Pharmacological inactivation of N-WASP fully abrogated 
	 vi 
insulin-stimulated GLUT4 vesicle translocation to the cell surface, coordinate with 
blunted F-actin remodeling. 
 Furthermore, my studies revealed new insulin-induced interactions amongst N-
WASP, actin, p41-ARC and PAK1; inactivation of PAK1 signaling blocked these 
dynamic interactions. Taken together, the above studies demonstrate the 
significance of PAK1 and its downstream signaling to F-actin remodeling in 
insulin-stimulated GLUT4 vesicle translocation and glucose uptake, revealing 
new signaling elements that may prove to be promising targets for future 
therapeutic design. 
Debbie C. Thurmond, Ph.D., Co-chair 	
Jeffrey S. Elmendorf, Ph.D., Co-chair 
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1.1. OVERVIEW OF DIABETES 
Glucose is the principal cellular energy source in humans. Hence maintenance of 
glucose homeostasis is critical for survival. There is an elaborate network of 
regulatory mechanisms, involving multiple organs and endocrine systems, 
developed to control the levels of glucose in the body. After the consumption of 
food, there is an increase in glucose levels in the blood due to digestion. This 
increase in blood glucose level triggers the pancreatic β cells to secrete the 
hormone insulin into the blood stream. Insulin then communicates with peripheral 
tissues of the body (such as skeletal muscle and adipose tissues) to increase the 
absorption of excess glucose, and with the liver to limit its production of glucose, 
culminating in the restoration of resting level of blood glucose. Conversely, during 
fasting conditions, the decrease in blood glucose levels signals pancreatic α cells 
to secrete the counter-regulatory hormone glucagon, which then enhances the 
production and secretion of glucose into the blood by the liver. These 
coordinated actions of insulin and glucagon maintain glucose homeostasis and 
euglycemia. Any abnormalities in these regulatory mechanisms lead to 
breakdown of glucose homeostasis, prompting metabolic abnormalities that can 
precipitate the development of ‘Diabetes’. 
Diabetes is a complex metabolic disorder with multiple etiologies resulting in 
dysregulation of glucose homeostasis wherein glucose levels are higher than the 
normal range (hyperglycemia). The normal range of blood glucose levels in 
healthy individuals are 70 – 100 mg/dL during the fasting state, and less than 140 
mg/dL during post-prandial state [1].  According to the Center for Disease Control 
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(CDC), as of 2012 there are 29.1 million diabetes patients in the United States, 
and additional 86 million Americans with pre-diabetic conditions. The American 
Diabetes Association classifies an individual as prediabetic or diabetic based on 
the fasting blood glucose levels. In prediabetic patients the fasting blood glucose 
levels are in the range of 100 – 125 mg/dl and in diabetic patients the levels are 
above 125 mg/dL. There are four types of diabetes: 
a) Type 1 (T1D, also called Juvenile diabetes) – Type 1 diabetic patients 
make up ~5-10% of adult diabetic patients.  This is  an autoimmune 
disorder wherein insulin secreting β-cells are destroyed by the immune 
system resulting in decreased insulin production and thus increased blood 
glucose levels.  
b) Type 2 (T2D) – Type2diabetes (also known as non-insulin dependent 
diabetes mellitus) is a chronic metabolic disorder characterized by high 
blood glucose levels (hyperglycemia) due to three key defects: 1) 
increased hepatic glucose production, 2) failure to secrete sufficient insulin 
and 3) impaired insulin action in liver and peripheral tissues such as 
skeletal muscle and adipose tissues (also termed as insulin resistance). 
Insulin resistance is discussed in detail in section 1.2. Approximately 90% 
of adult diabetic patients have type 2 diabetes and it has been well 
established that obesity and physical inactivity are the two major risk 
factors for the development of this disorder. Dysregulation of metabolism 
in T2D which is also known as a multiorgan disease affects all the other 
organs/ tissues that result in secondary complications including 
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hypertension, non-alcoholic fatty liver disease and metabolic syndrome all 
of which are associated with increased cardiovascular problems.  
c) Gestational diabetes – According to the CDC, the prevalence of 
gestational diabetes is around 4-9% of pregnancies. This occurs in women 
around the 24th week of gestation. Gestational diabetes is characterized 
by insulin resistance in pregnant women, leading to increased blood 
glucose levels. Nearly 5-10% of women develop T2D just after pregnancy, 
and around 8-13 % will have ~60% chance of developing T2D later in their 
life. 
d) Maturity-onset diabetes of young (MODY) – This accounts for 1-2% of 
the diabetic patient population. MODY is caused by genetically heritable 
mutations. These mutations are monogenic and are autosomal dominant. 
The most common genetic mutations in MODY occurs in glucokinase 
(GCK) and hepatocyte nuclear factor (HNF) 1A/4A genes. Mutations in 
GCK cause mild and stable fasting hyperglycemia. Mutations in HNF1A 
and HNF4A cause progressive pancreatic β-cell dysfunction. 
1.2. INSULIN RESISTANCE  
In a healthy individual, the pancreatic β-cells synthesize insulin constantly 
irrespective of the blood glucose levels. The synthesized insulin is stored in 
granules, and once the β-cells are triggered by elevation of blood glucose levels, 
the granules fuse with the plasma membrane and insulin cargo is released into 
the bloodstream. In the bloodstream, insulin then travels to and impacts various 
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insulin-responsive cell types of the body. Binding to the insulin receptor at the cell 
surfaces of skeletal muscle cells and adipocytes, insulin evokes an increase in 
the uptake of glucose into these cells, thereby decreasing the blood glucose 
levels. However, when insulin no longer is able to elicit its blood glucose-lowering 
effects, condition called ‘insulin resistance’ ensues [2]. In this condition, the body 
produces insulin, but cannot respond to normal levels of the insulin to maintain 
normal blood glucose levels. As a result, hyperglycemia occurs and in order to 
compensate for this, β cells increase insulin production by increasing their mass 
to be able to release much higher than normal levels of insulin into the 
bloodstream. In time this stress to overproduce insulin results in β cell 
dysfunction and the beta cell can no longer cope with the hyperglycemia, leading 
to destruction of the β cells. This results in decreased insulin production, and the 
development of frank T2D. Thus, insulin resistance is a pre-stage before T2D. 
Insulin resistance is considered to be a post-insulin receptor disorder, wherein 
the problem lies with the cells that respond to insulin rather than cells that 
produce insulin. Though several mechanisms have been proposed to explain the 
pathogenesis/etiology of insulin resistance, three mechanisms are widely 
accepted: ectopic lipid accumulation, development of endoplasmic reticulum (ER) 
stress and systemic inflammation [3].  
1.2.1. Ectopic lipid accumulation 
There is a strong connection between obesity and T2D [4]. Continued exposure 
of tissues to nutrient overload results in accumulation of toxic byproducts in 
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insulin responsive cells, especially lipid-derived metabolites that accumulate in 
liver, skeletal muscle and heart in response to high-fat diets. The current theory 
in the field is that high-fat diet induces accumulation of lipid species in cells due 
to impairment of normal fatty acid oxidation. As a result diacylglycerols (DAGs), 
ceramides and triglycerides are accumulated in cells [3, 5-7]. DAGs, being 
intracellular signaling molecules, activate Protein kinase C (in skeletal muscle, 
PKCθ), that in turn blocks activation of insulin receptors. Similarly, ceramide 
impairs activation of V-AKT Murine Thymoma Viral Oncogene Homolog 2(AKT2) 
by activating protein phosphatase 2A, which dephosphorylates AKT2. Thus, 
insulin signaling is inhibited due to accumulation of lipid species due to 
incomplete oxidation of fatty acids [7].  
1.2.2. Development of ER stress 
In response to excess nutritional exposure such as high fat diets, insulin 
secreting tissues such as pancreatic β cells and insulin sensitive tissues such as 
adipose tissue and liver develop ER stress, which in turn activates the unfolded 
protein response (UPR) [8]. New reports suggest that the UPR negatively 
regulates insulin signaling and also increases lipid accumulation in liver and 
adipose tissue [9], which in turn causes insulin resistance. 
1.2.3. Systemic inflammation 
The innate immune system is known to play a major role in insulin resistance in 
obese patients. The expression of Tumor necrosis factor (TNF)-α is increased in 
adipose tissues of obese subjects, and this increased TNF-α derived from 
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activated macrophages located within the adipose tissue (adipose tissue 
macrophages, ATMs) [10-12]. These ATMs are recruited by the chemokines 
Monocyte chemoattractant protein-1(MCP1) or C-C Motif chemokine ligand-2 
(CCL2) that are expressed by adipocytes present in the adipose tissue matrix. 
The increased TNF-α released from the ATMs stimulates NF-κB signaling in the 
adipocytes, leading to the increased production and release of cytokines, such as 
IL-1 and IL-6 by the adipose tissue. IL-6 then increases adipocyte lipolysis and 
blocks insulin signaling by promoting degradation of the insulin receptor 
substrates 1 and 2 (IRS1 and IRS2), thereby decreasing binding of IRS1 and 
IRS2 to insulin receptors, impeding the progression of the insulin signaling 
cascade [3]. 
It is now clear that metabolic aberrations, ER stress and inflammatory signaling 
are all associated and influence each other. Deciphering these mechanisms at 
the molecular level is crucial to understand the insulin signaling mechanisms 
under pathological conditions in order to develop new therapeutic strategies to 
combat progression to T2D. 
1.3. GLUCOSE TRANSPORTERS 
Whole body glucose homeostasis is maintained by three critical steps: 1) 
postprandial glucose absorption into the small intestine, 2) synthesis and 
production of glucose by the liver, and 3) glucose uptake by all the tissues. 
Glucose uptake /transport of glucose across cellular membranes in mammalian 
cells occurs via two major types of transporters, namely sodium-dependent 
glucose transporters (SGLTs) and glucose transporters (GLUTs). 
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1.3.1. Sodium-dependent glucose transporters (SGLT) 
This transporter family consists of six isoforms, SGLT1-SGLT6 [13-15], each of 
which co-transports glucose along with sodium ions. In the intestine, SGLTs 
facilitate transport across the apical membrane of the intestinal epithelium; this is 
driven by the concentration gradient of each on either side of the membrane[16]. 
This concentration gradient is maintained by the coordinated actions of two 
facets to the SGLT co-transporters: the energy-driven sodium/potassium ATPase, 
which transports sodium ions, and a glucose transporter that transports glucose 
across the basolateral membrane into the circulation.  
SGLT2 inhibitors such as Canagliflozin [17, 18] [19](Trade name-Invokana) and 
Dapagliflozin [20] (Trade name-Farxiga) are the newly developed oral anti-
diabetic drugs on the market, and are also available in combination with 
metformin (first line medication for treatment of T2D). SGLT2 inhibitors have a 
unique mechanism of action, in which they inhibit re-absorption of glucose in the 
proximal convoluted tubules (PCT) of kidney to facilitate its excretion in urine [21, 
22]. This action is dependent on blood glucose levels but not on the action of 
insulin. However, these medications carry a risk of side effects, including diabetic 
ketoacidosis, acute kidney injury and cardiovascular complications [23]. 
Nevertheless, their unique mechanism of action and positive pleotropic effects to 
reduce body weight and blood pressure make them attractive options as add-on 
therapies for T2D patients not well-controlled by other medications [24]. 
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1.3.2. Glucose transporters (GLUTs) 
As opposed to the passive glucose transport of the SGLTs, GLUTs mediate the 
facilitative transport of glucose. GLUTs comprise 14 family members (GLUT1-
GLUT14) located in a variety of tissues. Each GLUT isoform contains the 
characteristic 12 transmembrane helices, and a conserved N-glycosylation 
consensus site (Asn-X-Ser/Thr) typically positioned in the first or fifth exofacial 
loop between the transmembrane helices [25]. Based on primary sequence 
comparisons, GLUT family proteins are divided into three sub-classes: Class I, II 
and III facilitative transporters [26]. 
a) Class I facilitative transporters – GLUT1-4 and -14 belong to the 
Class I transporters. GLUT1 is the most extensively studied and is 
ubiquitously expressed. With highest expression levels in erythrocytes and 
endothelial cells of the brain [27], GLUT1 catalyzes the rate limiting step in 
supplying glucose to the cells of central nervous system. Supporting this, 
studies by Seidner et al have linked GLUT1 deficiency in humans to 
defective transport of glucose across the blood brain barrier [28]. GLUT2 
is the low affinity yet high capacity glucose transporter with predominant 
expression in pancreas, liver, kidney and basolateral membranes of the 
small intestine. GLUT2 transports the majority of the glucose into the liver, 
and plays a vital role in glucose-stimulated insulin secretion from 
pancreatic β cells [29, 30]. In a study by E Brot-Laroche et al (2003) using 
pre-fasted mice, the recruitment of GLUT2 to the apical membrane of the 
intestinal epithelium was demonstrated to occur within minutes in 
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response to a glucose bolus and the elevation of circulating glucose 
concentration [31]. GLUT2 has the highest Km (~17 mM) for glucose 
amongst the 14 GLUT family members. GLUT2 also transports galactose, 
fructose, and mannose; GLUT2 transports glucosamine with even higher 
affinity [32]. GLUT3 is high-affinity glucose transporter (Km=1.4 mM), and 
is predominantly expressed in tissues with high glucose demand, including 
brain, testes and placenta. Additionally, GLUT3 is present in platelets, 
lymphocytes and neutrophils. In lymphocytes GLUT3 was localized to 
vesicles that underwent stimulus-induced translocation from an 
intracellular locale to the plasma membrane [33]. In a process analogous 
to this, GLUT4 was also found to translocate to the cell surface of insulin 
responsive cell types such as skeletal muscle, adipose tissue and cardiac 
muscle [34]. Since its discovery in 1989, GLUT4 translocation has been 
noted as the rate-limiting step of insulin-stimulated glucose uptake into 
peripheral tissues. More details about GLUT4 and its regulation are in 
section 1.3.3. GLUT14, which is 95% identical to GLUT3, is exclusively 
expressed in testis and is suggested to be a product of gene duplication of 
GLUT3 [35]. With no orthologue in mice [36], GLUT14 has no known role 
in glucose metabolism in expressed tissue. 
b) Class II facilitative transporters – The class II family of GLUTs 
includes GLUT5, GLUT7, GLUT9 and GLUT11. This classification is 
based on the substrate specificity of each for fructose. Amongst these, 
GLUT5 is predominantly expressed in small intestine, with lower levels of 
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expression in kidney, brain and testis. GLUT5 is the major fructose 
transporter apart from GLUT2, yet has only minimal activity in glucose 
transport. Moreover, growing evidence suggests a correlation between 
GLUT5 expression levels and fructose uptake rates, with that of metabolic 
disturbances underlying conditions such as obesity, hypertension and 
diabetes. GLUT7 has ~74%	 amino acid sequence similarity to that of 
GLUT5 [37], and is expressed primarily in the apical membrane of small 
intestine and colon [38]. GLUT7 is the most recently characterized GLUT, 
found to have high affinity for glucose and fructose (Km for glucose and 
fructose = 0.3mM) [38]. However, because the distribution of GLUT7 in 
small intestine (primarily expressed) does not entirely match with the 
availability of glucose and fructose [37], these are not considered to be the 
physiological substrates for GLUT7. GLUT9, initially discovered as a high-
affinity glucose (Km=0.6 mM) / fructose (Km=0.4 mM) transporter, has 
also been identified as a high-affinity uric acid transporter (Km=0.9 mM) 
that plays a major role in urate homeostasis [39]. GLUT11, another 
fructose transporter, has low affinity for glucose (Km=0.16 mM) [40, 41] 
and is predominantly expressed in pancreas, kidney and placenta, with 
moderate expression levels in heart and skeletal muscle. Unlike GLUT4, 
GLUT11 is exclusively expressed in slow twitch muscle fibers, with no 
changes reported to its expression levels under pathophysiological 
conditions [42]. 
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c) Class III facilitative glucose transporters – Though classified third of 
the three classes of GLUTs, the class III GLUTs are suggested to have 
evolved before the class I and II transporters, having the highest 
homologies with different transporters in yeast, bacteria and Drosophila 
melanogaster [43]. There are structural features common to all of the 
class III transporters: an N-glycosylation site at the fifth extracellular loop, 
and an internalization signal (dileucine) that is required for the intracellular 
localization under steady-state conditions. The low affinity glucose 
transporter, GLUT6, is predominantly expressed in brain, spleen and 
leukocytes, and has been suggested to have no role in insulin-stimulated 
glucose uptake. Unlike GLUT6, GLUT8 has a high affinity for glucose 
(Km~2 mM) [44] and GLUT8’s activity is specifically inhibited by D-
fructose and D-Galactose, suggesting it to be a multifunctional transporter 
[44]. Predominantly expressed in testes, GLUT8 has also been detected in 
insulin-sensitive tissues such as heart and skeletal muscle. Interestingly, 
recent studies using GLUT8 deficient mice fed a high-fructose diet 
revealed the potential role of GLUT8 to be in mediating deleterious effects 
of fructose in inducing glucose intolerance and dyslipidemia [45]. These 
data suggest GLUT8 to have potential as a novel therapeutic target to 
treat or possibly prevent obesity and metabolic syndrome. GLUT10 is 
predominantly expressed in liver and pancreas, and while GLUT10 is 
localized within the T2D-linked region on human chromosome 20q12-13.1, 
GLUT10 polymorphisms were not associated with T2D in humans [46-48]. 
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GLUT12 is largely expressed in insulin-responsive tissues such as 
pancreas, skeletal muscle and adipose tissue, and is considered as the 
secondary insulin-sensitive glucose transporter behind GLUT4, due to its 
translocation to the plasma membrane along with GLUT4 in response to 
insulin in skeletal muscle [49]. Finally, GLUT13, also called H+/-myo-
inositol transporter (HMIT), is predominantly expressed in brain and 
contains all of the motifs required for glucose transport activity.  
Surprisingly however, GLUT13 transports myo-inositol with a Km of 100 
µM [50] and lacks sugar transport activity. 
1.3.3. GLUT4 is the major insulin-responsive glucose transporter 
The major route of clearance of postprandial serum glucose is via the skeletal 
muscle. In skeletal muscle, glucose is oxidized to meet the energy demands of 
the cell, and glucose is also stored as energy in the form of glycogen following 
glucose transport. Of the 13 currently identified sugar transporter proteins known, 
the principal glucose transporter that mediates glucose clearance and uptake into 
skeletal muscle to regulate whole body glucose homeostasis, is GLUT4. While 
skeletal muscle also contains GLUT1, GLUT5 and GLUT12, which contribute 
significantly to the glucose uptake, GLUT4 is the only insulin-responsive GLUT 
that redistributes from intracellular regions to the plasma membrane in response 
to insulin. The GLUT4 protein contains unique phenylalanine residues in the N-
terminal sequence [51-55], as well as dileucine and acidic motifs in the C-
terminal region [56-60], which are thought to facilitate its membrane trafficking 
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capability. Moreover, both the amino- and carboxy-termini of GLUT4 are located 
in the cell interior/cytoplasm.  
Early evidence for the significance of GLUT4 in the maintenance of whole-body 
glucose homeostasis comes from studies using classic, whole-body 
heterozygous GLUT4+/- gene ablated mice, with reduced GLUT4 expression 
both in skeletal muscle and adipose tissue [61, 62]. As consistent with the prior 
ex vivo work on GLUT4, the heterozygous GLUT4+/- mice exhibited insulin 
resistance and predisposition toward diabetes. In contradiction however, the 
whole-body homozygous GLUT4-/- knockout mice demonstrated no major 
metabolic defects [63]; studies suggested this was due to possible upregulation 
of compensatory mechanisms. Later, transgenic mice engineered to overexpress 
GLUT4 in adipose or skeletal muscle tissues were highly insulin-sensitive and 
glucose tolerant [64-66], supportive of the important physiological reliance upon 
GLUT4 in these tissues for the overall regulation of whole-body glucose 
homeostasis. 
1.3.4. Endogenous expression and tissue distribution of GLUT4 
Maintenance of glucose homeostasis requires the concerted action of different 
insulin-secreting tissues as well as insulin-sensitive tissues - any defect in one or 
more tissue types results in T2D. Insulin-sensitive tissues act by mobilizing the 
GLUT4 containing vesicles from intracellular pools to the plasma membrane 
(PM) in response to insulin [67-69], and this increases the glucose uptake by 10-
20 fold. While GLUT4 is widely distributed in insulin-responsive tissues including 
skeletal muscle, brown adipose tissue (BAT), white adipose tissue (WAT) [70, 
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71] and heart, it is also in brain and has been proposed to translocate in 
response to insulin to contribute to whole-body glucose homeostasis in sync with 
the other GLUT4-expressing tissues. Studies of tissue–specific/conditional 
GLUT4 knockout mouse models have shed light upon the relative contribution in 
each tissue in isolation to overall glucose homeostasis [72]. For example, mice 
deficient in GLUT4 specifically in skeletal muscle exhibited severe insulin 
resistance and glucose intolerance at an early age [73]. Similarly, adipose-
selective depletion of GLUT4 in mice led to impaired glucose tolerance and 
hyperinsulinemia, indicating a critical role of adipose tissue in glucose 
homeostasis [74]. The data showing importance of GLUT4 expression and 
function in skeletal muscle and adipose tissue translate to human findings as well. 
In particular, decreased GLUT4 levels in adipose tissue correlate with increased 
obesity in humans, and conversely, increased GLUT4 expression is seen in 
exercised individuals [75-78]. Towards this, a 2.4 kb DNA segment at the 5’ 
region of human GLUT4 gene has been identified as the regulatory element for 
the tissue specific expression of GLUT4 (at the transcription level) in adipose, 
skeletal muscle and cardiac muscle tissues [70, 79]. Discovering new regulatory 
elements for tissue specific expression in metabolic tissues that regulate 
circulating glucose levels will provide new avenues and strategies to treat this 
debilitating disease.  
1.4. GLUCOSE UPTAKE INTO SKELETAL MUSCLE 
1.4.1. Insulin-independent/ Contraction-stimulated glucose uptake in 
skeletal muscle 
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In brief, contraction and exercise-induced glucose uptake is regulated at three 
different levels- 1) Skeletal muscle GLUT4 expression, 2) GLUT4 mobilization to 
the sarcolemma and T-tubules and 3) Glucose transport/ uptake into skeletal 
muscle. 
1.4.1.1. Skeletal muscle GLUT4 expression: 
Evidence for the regulation of skeletal muscle GLUT4 expression impacting 
glucose homeostasis stems from early studies in 1996 [65], where transgenic 
mice overexpressing GLUT4 in skeletal muscle showed improved glucose 
tolerance and, enhanced glucose disposal. Since then, much focus has been 
shifted towards identifying therapeutic strategies to increase the expression of 
GLUT4 as a means to address metabolic disorders including insulin resistance, 
metabolic syndrome/prediabetes and T2D. The levels of GLUT4 expression differ 
in different skeletal muscle fiber types, with higher expression levels of GLUT4 in 
the type I oxidative fibers (soleus muscle) compared to the glycolytic type II fibers 
(epitrichlearis and extensor digitorum longus (EDL)) [80-82]. Longer duration 
exercise is implicated in the conversion of type II to type I muscle fibers [83], 
increasing the efficiency of the muscle in utilizing glucose; i.e. type I muscle 
fibers produce more ATP (being oxidative goes through mitochondria) than 
glycolytic (anerobic glycolysis) which produces less ATP per glucose molecule. 
For example, in as few as 3 hours post-swimming, including a 45 min rest period, 
an increase in GLUT4 mRNA expression associated with a surge in GLUT4 
protein expression is observed [84, 85].  
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Two key domains in the GLUT4 promoter region have been identified that 
regulate the GLUT4 gene expression specifically in adipose tissue, skeletal 
muscle and cardiac muscle. The first region, Domain 1, is activated by the 
binding of glucose enhancer factor (GEF) and members of the myocyte enhancer 
factor 2 (MEF2) family of transcription factors, MEF2A and MEF2D. The second 
region, the MEF2 domain, contains an apparent MEF2 binding region, and has 
been suggested to confer tissue specific expression [86]. Conversely, the 
transcriptional repression of MEF2 is carried out by HDAC5, a class II histone 
deacetylase (HDAC). Specifically, GEF and MEF2 were discovered as the 
regulatory elements that control the tissue specific expression of GLUT4 gene in 
skeletal muscle [87, 88]. GEF and MEF2 activities are initiated by a surge in 
AMP/ATP ratio and intracellular calcium concentrations during exercise. This in 
turn induces the activation of the energy sensor of the cell, 5’-AMP activated 
protein kinase (AMPK) and Ca2+/calmodulin-dependent protein kinase (CAMK) II, 
respectively. Activated AMPK and CAMK II increase GEF and MEF2A DNA 
binding [89-91], as well as to remove the HDAC5 repression (by increasing its 
nuclear export), to ultimately increase GLUT4 mRNA expression.  
1.4.1.2. GLUT4 mobilization to sarcolemma and T-tubules: 
The number of GLUT4 proteins integrated into the cell surface/PM depends on 
the rate of endocytosis and exocytosis of GLUT4-containing vesicles in response 
to various stimuli. Although insulin is known to regulate this mobilization process, 
primarily by increasing the GLUT4 vesicle exocytosis, exercise/ contraction both 
increases GLUT4 exocytosis and decreases GLUT4 endocytosis. Studies by Klip 
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et al demonstrated that acute insulin injection into rat hindlimb muscle (in vivo) 
resulted in a surge of GLUT4 transporters to the PM fractions, accompanied by a 
decrease in the intracellular membrane fractions. Interestingly, exercise similarly 
increased GLUT4 content in the PM fractions, however failed to decrease GLUT4 
levels in the intracellular fractions. Moreover, both insulin and exercise utilize 
different signaling pathways, suggesting that two distinct pools of GLUT4 
containing vesicles are transported from perinuclear regions to the sarcolemma 
and T-tubules [92] in response to insulin and contraction. The additive effects of 
exercise and insulin treatment on glucose uptake by rat skeletal muscle support 
this two-pool concept [93, 94]. The initiation of insulin- and contraction-stimulated 
GLUT4 vesicle mobilization involves two distinct molecular signaling pathways 
that partially converge in their distal aspects, e.g. TBC1D1, TBC1D4 [95-101] 
and Rac1 [102]. 
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Figure 1. 1. Translocation of GLUT4 to sarcolemma and transverse tubules 
of skeletal muscle. Exercise induces a surge in intracellular calcium 
concentration and AMP/ATP ratio, which leads to the activation of AMPK. 
Activation of AMPK results in the activation of at least two pathways that lead to 
GLUT4 translocation: 1) activation of the small family Rho GTPase, Rac1, which 
facilitates actin remodeling-induced GLUT4 vesicle mobilization; 2) the 
phosphorylation and inactivation of TBCID1, and subsequent activation (via GTP 
loading) of Rab proteins. Possibly linked wth the Rac1 pathway, Myo1c, an actin-
based motor protein, has also been shown to be a novel mediator of both insulin 
as well as contraction-induced glucose uptake in skeletal muscle [103].  
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1.4.1.3. Glucose transport/ uptake into skeletal muscle: 
Three processes that dictate contraction-induced glucose uptake/ transport into 
skeletal muscle include glucose delivery [104-106], glucose transport and the 
metabolism of glucose after its entry into the cell. Exercise-induced increase in 
blood flow to the skeletal muscle results in net increase in glucose uptake, due to 
the increased glucose and insulin delivery to the skeletal muscle, along with 
recruitment of capillaries which increases the surface area for glucose delivery. 
Moreover, glucose transport/ uptake into the cell depends on the cell surface 
GLUT4 levels, which requires the translocation and fusion of GLUT4 from 
intracellular sites to the sarcolemma and T-tubules (detailed in section 1.4.1.2). 
Once glucose enters into the cell it undergoes immediate phosphorylation to 
glucose-6-phosphate (G-6-P) due to the action of Hexokinase II (HKII).  
1.4.2. Insulin-dependent glucose transport and Glucose transporter 
translocation in skeletal muscle 
Insulin mediates both metabolic and mitogenic responses to control diverse 
processes including cellular growth, differentiation, apoptosis, lipid, protein and 
glucose synthesis and breakdown. Failure to regulate these processes results in 
profound metabolic consequences, including insulin resistance and T2D. Insulin 
signals the decrease in hepatic glucose output into the blood stream, coordinate 
with signaling the increases in GLUT4-dependent glucose uptake into the 
peripheral tissues, altogether regulating whole body glucose homeostasis. 
GLUT4 is the major contributor amongst all 14 of the GLUTs for the insulin-
induced glucose disposal by peripheral tissues, and the acute insulin-stimulated 
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increase in surface GLUT4 is the major phenomenon required to accomplish this 
job. The insulin-induced surge in surface GLUT4 into adipocytes is achieved by 
decreasing the endocytosis/ internalization of GLUT4 and increasing the 
exocytosis/ externalization of GLUT4. However, in skeletal muscle, insulin does 
not affect the rate of GLUT4 endocytosis. This implicates an elevated rate in 
GLUT4 exocytosis/ externalization as the primary mediator of the gain in insulin-
stimulated surface GLUT4 levels. 
1.4.2.1. Journey of GLUT4: from endocytosis to exocytosis: 
The increase in cell surface GLUT4 in response to insulin is predominantly due to 
the increased exocytosis of GLUT4 in skeletal muscle; in adipocytes, this is also 
impacted, albeit to a lesser extent, by decreased endocytosis into sorting 
endosomes.  
a) Endocytosis – Clathrin-mediated endocytosis and cholesterol-
dependent endocytosis are the two major endocytosis pathways of GLUT4 
[107]. Although historically it was assumed that clathrin was the major 
operating pathway in skeletal muscle cells, a study in L6 myoblasts 
demonstrated that depletion of cholesterol could exert a notable inhibition 
of GLUT4 internalization and endocytosis [107], lending support for 
cholesterol-dependent endocytosis as a required process in skeletal 
muscle cells. Regarding the mechanisms involved in clathrin-mediated 
endocytosis [108], Adaptor Protein 2 (AP2) binds to GLUT4 and recruits 
clathrin to the PM, where it packages GLUT4 into clathrin-coated vesicles, 
and these are pinched off the membrane with the help of Dynamin. Newly 
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formed vesicles/ early endosomes at the PM that carry GLUT4 are 
transported to the cell interior by microtubule-based motor protein, Dynein. 
Dyein is attached to the GLUT4-containing vesicles via Rab5 (Fig. 1-1). 
Endocytosed vesicles fuse with the sorting endosomes that are either 
subjected to degradation or recycling. The GLUT4 transporter can be 
recycled back to the plasma membrane by budding off into GLUT4 
storage vesicles (GSV) from recycling sorting endosomes with the help of 
small Rho family GTPases specifically Rab 4, Rab 5, Rab 11 and RalA. 
Insulin causes a 10-40 fold increase in surface GLUT4 by facilitating 
GLUT4 exocytosis from GSVs and sorting endosomes. In contrast, GSVs 
can be directed to alternate intracellular regions, where they undergo futile 
cycles between GSV and the trans-Golgi network (TGN); this aspect is 
activated by Rab31 and occurs in the absence of insulin. GLUT4, along 
with insulin-regulated amino peptidase (IRAP), sortilin and low-density 
lipoprotein receptor-related protein-1 (LRP1), forms a multimeric protein 
complex that is packaged into a releasable GSVs. Insulin stimulation 
triggers the inactivation of Rab31 coordinate with the activation of the 
small GTPase, ARF6 to increase GSV release from the endosomal 
recycling compartment. 
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Figure 1.2. Endocytosis and Exocytosis of GLUT4. Schematic model showing 
clathrin and cholesterol-mediated endocytosis as well as microfilament and 
microtubule-dependent exocytosis of GLUT4 in Insulin-responsive tissues. 
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b) Exocytosis – The exocytosis of GSVs requires their translocation to 
the PM, docking at PM sites, and fusion with the PM. Translocation of 
GSVs is proposed to initiate in response to the insulin signal triggering 
release of GSVs from TUG (Tether containing a ubiquitin regulatory X 
(UBX) domain of GLUT4). Inducing endoproteolytic cleavage of TUG, 
liberates intracellularly-sequestered GSVs from a retention pool, 
permitting their translocation to the PM [109, 110]. In skeletal muscle, this 
involves the activations of small GTPases Rab8 and Rab14. GSVs, like 
most other secretory vesicles, utilize the actin-based myosin for 
translocation across short distances (i.e. transport or GSVs less than 1 µm 
to the PM [110].. GSVs use microtubule-based kinesins for longer 
distances from perinuclear regions to the PM. Myosin and kinesin motor 
proteins implicated in this type of process include MYO5A and MYO1C, 
and KIF3 and KIF5A, respectively. While adipocytes have been shown to 
use both kinesin- and myosin-based motor proteins to transport GSVs, 
skeletal muscle cells predominantly use actin-based myosin motors 
(detailed in section 1.5). In skeletal muscle, the myosin-motor protein 
MYO1C recognizes the small GTPase RalA present on the GSV 
membrane, and transports the GSV on the actin cytoskeletal tracks to the 
docking/targeting site on the PM. In adipocytes it has been further 
elucidated that GTP-loaded RalA transports GSV to the targeting site via 
its interaction with exocyst subunits, SEC5 and EXO84. The exocyst 
subunits are part of a larger exocyst complex, composed of eight distinct 
	 25 
proteins including Sec3, Sec5, Sec6, Sec8, Sec10, Sec15, Sec4 and 
Exo70. This exocyst complex is stabilized at the PM by the insulin-induced 
activations of AKT and the small GTPase TC10, along with the action of 
the lipid raft-localized synapse-associated protein 97 (SAP97). 
Subsequent to this docking step, the protein kinase C (PKC)-dependent 
phosphorylation of the protein SEC5 inhibits the interaction of RalA and 
the exocyst complex, disengaging the GSV from the targeting/docking 
machinery to prepare the GSV for fusion with the PM. GSV fusion requires 
SNARE complexes composed of the GSV-based vesicle-SNARE vesicle 
associated membrane protein-2 (VAMP2), and two PM-localized target-
SNARE proteins, Syntaxin 4 and synaptosomal-associated protein 23 
(SNAP-23).  Docking and fusion of GSVs also requires the recruitment of 
double C2-like domain containing protein β (Doc2β) to the PM. Doc2β 
sequesters the regulatory protein Munc18c and facilitates activation/ 
opening of Syntaxin 4, which once opened, participates in the SNARE 
complex formation leading to GSV exocytosis. 
1.5. THE ROLE OF THE ACTIN CYTOSKELETON IN GLUT4 EXOCYTOSIS  
Signaling to and consequent sorting of GSVs from the intracellular regions of the 
muscle cell to the docking/fusion sites at the PM requires spatiotemporal 
regulation of components of the dynamic cytoskeleton. In adipocytes, multiple 
studies using disrupting agents of either KIF3 or KIF5b have suggested both 
actin- and microtubule-based cytoskeletal regulations are required for the insulin-
induced mobilization of GSVs to the PM [111]. Contrary to this concept, 
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disruption of microtubule-based motors using the pharmacological agent 
colchicine in skeletal muscle cells (L6 muscle cells) failed to impair the insulin-
induced GSV translocation to the PM[112]. Supporting the actin-based 
mobilization concept, treatment of L6 cells with the inhibitor of actin branching, 
Swinholide A, blunts GLUT4 translocation and membrane ruffling, [112, 113]. 
Moreover, depolymerization of filamentous actin (F-actin) by the actin monomer 
sequestering agent, Latrunculin B, exhibits a time- and concentration-dependent 
decline in glucose transport into muscle cells, implicating the requirement of an 
intact F-actin network for insulin-induced GLUT4 translocation and glucose 
uptake [114]. Interestingly, knockdown of Myo1c in L6 muscle cells disrupted 
actin filaments, while Myo1c overexpression immobilized those GSVs close to 
the PM (as detected by total internal reflection fluorescence, TIRFM). As such, a 
prevailing concept is that the interaction of vesicular Myo1c with F-actin regulates 
GLUT4 vesicle tethering to the actin cytoskeleton and subsequent insulin-
induced GLUT4 vesicle fusion to the PM [115]. 
1.5.1. Insulin-induced F-actin remodeling and GLUT4 vesicle 
translocation  
Cytoplasmic actin exists in 2 forms: a) monomeric globular actin (G-actin) b) 
filamentous actin (F-actin). F-actin remodeling encompasses the process of 
continuous cycles of polymerization of actin at the barbed end of the existing 
filament, and depolymerization of F-actin to G-actin at the pointed end. Both F-
actin nucleating proteins, such as those of the Arp2/3 complex, with the opposing 
actions of actin severing proteins such as cofilin and gelsolin, tightly regulate this 
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F-actin remodeling process [116-118]. Importantly, multiple studies have shown 
that the insulin-stimulated remodeling of F-actin, as opposed to simply its 
polymerization, is essential for the translocation of GSVs to the PM of skeletal 
muscle cells [119, 120].  
1.5.1.1. Actin polymerizing proteins: 
Several actin nucleating/ branching proteins function together to regulate the 
intricate process of actin polymerization, of which the Arp2/3 complex, a 
branched actin filament nucleator, is implicated specifically in GLUT4 vesicle 
translocation in skeletal muscle cells. Arp2/3 is a 220 kDa complex consisting of 
seven subunits (ARP2, ARP3, ARPC1-5). From a structural perspective, the 
actin-related proteins (ARP2 and ARP3) resemble monomeric actin because 
together they seem to mimic an actin dimer, initiating the formation of new actin 
branches on existing F-actin filaments. Knockdown of ARP3 or ARPC2 subunit of 
ARP2/3 complex in skeletal muscle cells abrogated insulin-induced F-actin 
remodeling and GLUT4 translocation to the PM [121]. Intriguingly, PAK1, a well 
studied downstream effector of Rac1 that is involved in insulin-induced cortical 
actin remodeling, phosphorylates ARPC1, a regulatory subunit of the ARP2/3 
complex, to initiate actin remodeling in a mammalian breast cancer cell line 
(MCF-7) [122]. This suggests that PAK1 may act via the regulation of ARP2/3 
complex in skeletal muscle cells. Although the ARP2/3 complex can initiate 
branched actin filament nucleation, it requires the actions of nucleation promoting 
factors, such as N-WASP, WAVE and Cortactin, to stimulate its activity and carry 
out actin polymerization. 
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a) Nucleation promoting factors (NPF) – NPFs are classified into two 
classes: Type I NPFs interact with monomeric actin molecules, whereas 
Type II NPFs bind to the actin filaments. Recent findings by Nakaya et al 
[123] show that overexpressing Cortactin, a type II NPF, in L6-GLUT4myc 
cells increased insulin-induced GLUT4 translocation. Furthermore, 
knockdown of Cortactin completely blunted insulin-dependent glucose 
uptake into L6-GLUT4-myc myotubes. While these data clearly show a 
requirement for Cortactin in GLUT4 vesicle mobilization, Cortactin is 
considered to be a relatively weak activator of the Arp2/3 complex, and 
requires strong NPFs such as neural Wiskott Aldrich Syndrome Protein 
(N-WASP, also a type II NPF) to accomplish Arp2/3 mediated actin 
polymerization. Supportive of a role for N-WASP in muscle cells, Brozinick 
et al showed that N-WASP localized to F-actin in an insulin-dependent 
manner, and that this was abrogated by disruption of F-actin by 
Latrunculin B [114] in mature skeletal muscle. In non-muscle cells, PAK1 
has been shown to use Cortactin as a substrate, phosphorylating serines 
405 and 418, which increases its association with N-WASP and facilitates 
the polymerization of actin during clathrin-independent endocytosis [124]. 
While this would serve as a means to connect GSV mobilization via 
ARP2/3 and N-WASP with Cortactin, this has yet to be tested in skeletal 
muscle cells. To date, there are no reports implicating the role of any 
known type 1 NPFs in the mobilization of GSV to the skeletal muscle cell 
surface. 
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b) Actin stabilizers – Polymerizing actin is also stabilized by proteins 
such as Fodrin, also known as nonerythroid spectrin. Interestingly, Fodrin 
has been shown to interact with the t-SNARE syntaxin 4 in response to 
insulin, and hence is implicated in the fusion of GSVs with the PM in rat 
adipocytes [125]. Moreover, the Calpain-induced cleavage of Fodrin at the 
sarcolemma in muscle is associated with Duchenne Muscular Dystrophy 
(DMD) [126], a disease wherein insulin resistance is an early 
manifestation [127]. Increased cleaved fodrin is also found in pancreatic β 
cells of T2D subjects, further linking fodrin to metabolic control 
mechanisms in glucose homeostatic tissues/cells.   
c) Actin crosslinking proteins – Filamin A is an actin crosslinking protein 
that can be phosphorylated by PAK1 at Ser2152 and was shown to be 
involved in PAK1-dependent membrane ruffling in mammalian breast 
cancer cells [128]. Once phosphorylated, Filamin A interacts with the 
GTPase binding domain of PAK1, inducing its further activation and 
creates a feed-forward loop of activation of PAK1. In skeletal muscle, 
cross-sectional analyses show the colocalization of Filamin A with 
phosphoinositidylinositol 3,4,5 trisphosphate (PtdIns[3,4,5]P3) 5-
phosphatase (SHIP-2) in the membrane ruffles, and these are 
considered to be the sites of insulin-induced GLUT4 translocation. Taken 
together, these findings suggest a possible mechanism involving PAK1 
with Filamin A and SHIP-2 in GSV mobilization in skeletal muscle [129]. 
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1.5.1.2. F-actin severing/ depolymerizing and capping proteins: 
Actin depolymerizing factor (ADF)/ Cofilin and Gelsolin are the two major actin-
severing proteins implicated in the regulation of the skeletal muscle actin filament 
network [121]. In non-muscle cells, Cofilin phosphorylation at Ser3 by LIM-kinase 
(LIMK) inhibits Cofilin’s actin severing ability [130]. In contrast, Cofilin’s 
dephosphorylation at Ser3 by the phosphatase Slingshot (SSH) will activate 
Cofilin [131]. Recent findings by Wang et al [132]reveal the requirement of PAK1 
for the insulin-dependent dephosphorylation of phospho-Cofilin in skeletal muscle. 
Interestingly, PAK4 a Group II PAK member, has been shown to activate LIMK 
and inactivate SSH via phosphorylation in vitro, suggesting a plausible role in the 
inactivation of Cofilin [133]. However, the involvement of PAK4 as a potential 
regulator of Cofilin activity in skeletal muscle, rather in vivo is yet to be explored.  
Gelsolin, is a member of the class of actin severing proteins that mediate 
calcium-dependent severing and capping of actin filaments at their barbed ends. 
Gelsolin consists of six structurally similar domains (G1-G6) [134] and assumes 
an autoinhibitory form in the absence of activation, due to the intramolecular 
interaction of its C-terminal tail with the G2 domain (Fig. 1-2). Mechanistically, 
calcium binding to Gelsolin relieves it from the autoinhibitory state and increases 
its affinity for the ADP-associated actin filament to initiate its severing function 
[135]. Gelsolin is expressed ubiquitously [136], and has been implicated as a 
regulator of unsoliticed insulin secretion from pancreatic β cells. This concept is 
supported by a study showing Gelsolin bound to the t-SNARE protein Syntaxin 4 
and blocked Syntaxin 4 engagement in active vesicle fusion [137]. Given a 
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number of similarities in the SNARE mediated exocytosis machinery in the insulin 
granule exocytosis in pancreatic β cells and GLUT4 exocytosis in skeletal muscle, 
this carries the potential to be a shared mechanism in skeletal muscle GLUT4 
exocytosis. 
A second actin capping protein, Tropomodulin3, has been identified as a novel 
AKT2 interacting partner that is regulated by phosphorylation at Ser71 by AKT2 
in 3T3-L1 adipocytes. Knockdown of (Tmod3) abrogated insulin-induced GLUT4 
vesicle fusion and subsequent glucose uptake [138]. Moreover, TIRFM analysis 
of adipocytes showed a requirement for Tmod3 and its phosphorylation in insulin-
initiated actin remodeling. All together, the studies of these actin modifying 
factors link their actions to F-actin cytoskeletal reorganization and GLUT4 vesicle 
translocation/ exocytosis to the cell surface of insulin-sensitive tissues. 
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1.6. THE CANONICAL INSULIN SIGNALING PATHWAY IN SKELETAL 
MUSCLE 
The classic insulin signaling pathway in skeletal muscle cells initiates with insulin 
binding to the insulin receptor (IR) present on the extracellular surface of the 
skeletal muscle cell. Insulin binds to the extracellular α subunit of the tetrameric 
insulin receptor, which elicits a conformational change in the α subunit and 
receptor autophosphorylation at several tyrosine residues in the intracellular β 
subunit [139]. These phosphorylation events induce conformational changes in 
the intracellular IR subunits to further increase the catalytic kinase activity of the 
IR, resulting in the recruitment of its receptor substrates. Recruited IR substrates 
in this pathway include insulin receptor substrate (IRS) via pleckstrin homology 
(PH) domains and phosphotyrosine binding domains (PTB) in the IRS amino 
termini. In skeletal muscle, IRS-1, but not IRS-2 plays a critical role in myoblast 
differentiation and glucose metabolism[140, 141]. Downstream of IRS-1, the 
pathway branches into at least two major transduction routes, one in which upon 
tyrosine phosphorylation IRS-1 protein binds Src-homology-2 (SH2) domain 
containing proteins including p85, the regulatory subunit of class I 
Phosphatidylinositol-3 kinase (PI3K) and targets the enzyme to the membrane. 
At the membrane, PI3K phosphorylates phosphatidylinositol 4,5-biphosphate 
(PIP2) to produce the lipid second messenger phosphatidyl 3,4,5-triphosphate 
(PIP3) that recruits several PIP3 binding proteins to the membrane. In the other 
pathway, phosphorylated IRS-1 interacts with adaptor molecule, growth factor 
receptor bound protein 2 (GrB2) and son-of-sevenless (SOS) complex activating 
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Ras-MAPK cascade and mitogenesis. The IRS-1-PI3K pathway, which mediates 
insulin’s action on glucose metabolism, further bifurcates into at least two parallel 
signaling pathways downstream of PI3K (Fig. 1-3). 
1.6.1. The PI3K-AKT-AS160 signaling arm 
The insulin-stimulated recruitment of p85 by IRS1 brings p110, the catalytic 
subunit of PI3K to the PM, where it catalyzes the phosphorylation of the 3’ 
position on the inositol ring of the phosphoinositide (PI) lipids[142].. PI3K 
specifically catalyzes formation of PIP2 from PI(4)-phosphate; the PIP3 
generated from PIP2 then aides in the recruitment and activation of PIP3-binding 
proteins that contain pleckstrin homology (PH) domains, namely 
phosphoinositide-dependent-kinase 1 (PDK1) and AKT (protein kinase-B). Of the 
three AKT/PKB isoforms (AKT1, 2 and 3), AKT2/PKBβ has been shown to be 
essential for glucose transport into skeletal muscle, using whole body KO rodent 
models [143] as well as functional studies in skeletal muscle with in vivo 
electrotransfer of constitutively active-AKT2 (ca-AKT2) [144]. PIP3-guided PM 
recruitment of PDK1 and AKT2 aide in the phosphorylation and activation of 
AKT2T308 and of PDK1 and PDK2 (also known as mammalian target of 
Rapamycin complex 2[mTORC2]) at S473 [145, 146]. Fully activated AKT2 
phosphorylates one of its substrates, the Rab guanine nucleotide activating 
protein (GAP) called AS160T642 (also known as TBC1D4). 
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Figure 1.4. Insulin signaling pathway. Insulin binding to the insulin receptor 
(IR) and results in the activation of PI3K, downstream of which the pathway 
bifurcates into at least two signaling pathways: 1) Activation of Phosphoinositide 
dependent kinase-1 (PDK1) allows PDK1 to access and phosphorylate AKT. 
Activated AKT in turn phosphorylates ad inactivates Rab GTPase activating 
proteins AS160 and TBCID1, thus facilitating Rab.GTP mediated GLUT4 storage 
vesicle (GSV) translocation; 2) Activated Rac1 downstream of PI3K recruits its 
downstream effector PAK1 and initiates cortical F-actin remodeling which is 
regulated by actin binding proteins Cofilin and Arp2/3 complex. Cortical actin 
remodeling facilitates GSV translocation and fusion to the cell surface with the 
help of SNARE complex proteins, VAMP2, Syntaxin 4 and SNAP-23, and results 
in glucose uptake.   
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AS160 targets Rab8A and Rab14 in skeletal muscle [147] and inactivates each 
Rab. Through its GTPase activating domain, AS160 maintains Rab proteins 
(small G proteins involved in membrane trafficking) in an inactive GDP-bound 
state under basal/unstimulated conditions [148]. Upon dissociation from AS160, 
mediated by their phosphorylation and binding by the 14-3-3 protein, Rab 
proteins are switched to their active GTP-bound state to facilitate GSV trafficking 
to the PM. Interestingly, AS160 is also regulated by the action of AMPK, which is 
a key regulator of the contraction-induced glucose uptake pathway [99], placing 
AS160 at a point of convergence linking insulin-and contraction–mediated 
signaling (detailed in section 1.3.1.) to facilitate glucose entry into skeletal muscle.  
1.6.2. Rac1-PAK1-actin remodeling pathway 
 
In the last decade much emphasis has been placed on delineating the alternative 
pathway involving small Rho family GTPases, a pathway found to proceed in 
parallel to that of the AKT-AS160 pathway, downstream of PI3K. Rac1 (Ras-
related C3 botulinum toxin substrate 1) is a small Rho family GTPase that acts 
as a molecular switch to execute diverse cellular processes including cell cycle, 
cell-cell adhesion and actin cytoskeleton regulated motility, by changing between 
active GTP-bound form and inactive GDP-bound form. Recently, Rac1 has been 
shown to function downstream of PIP3, in the regulation of insulin-dependent 
GLUT4 vesicle translocation and glucose uptake into skeletal muscle. In skeletal 
muscle cells, the activation of Rac1 transmits signals to various downstream 
effectors involved in cytoskeletal remodeling. Although both AKT and Rac1 act 
downstream of PI3K [149], signaling pathways followed by each protein were 
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suggested to take parallel and independent routes to facilitate insulin-dependent 
glucose uptake in skeletal muscle. This was supported by multiple studies, using 
dominant negative mutants and pharmacological/chemical inhibitors of AKT [150], 
none of which showed any effect upon insulin-induced actin cytoskeletal 
remodeling. Consistently, neither Rac1 knockdown nor expression of the 
constitutively active Rac1 mutant altered insulin-stimulated AKT phosphorylation 
[139]. However, more recent studies by Takenaka et al using skeletal muscle 
specific Rac1 KO mice demonstrate significant reduction in AKT2 or PI3K 
dependent GLUT4 translocation in skeletal muscle, contradicting the above 
findings [151]. Despite this discrepancy, studies using both cell culture models as 
well as whole body KO mouse models have implicated Rac1 and its downstream 
signaling to p21-activated kinase 1 (PAK1) to be crucial regulators of both 
insulin- and contraction-induced cytoskeletal remodeling as a key element in 
regulated GLUT4 vesicle trafficking.  
1.6.2.1. Structure, activation and function of PAKs:  
PAK proteins are serine/threonine kinases that consists of 6 family members 
divided into two groups; Group I PAKs include PAK1, 2 and 3, Group II PAKs 
consist of PAK4, 5 and 6. The basic structure of Group I PAKs: each consists of 
an N-terminal regulatory domain, which includes a GTPase binding domain 
(GBD) that is also known as a Cdc42-Rac Interactive Binding (CRIB) domain, 
overlapping with an auto-inhibitory domain (AID), and a C-terminal kinase 
domain. Group I PAKs exist in an inactive homodimer conformation (unlike 
Group II PAKs, which exist as monomers), where the AID domain of one 
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monomer is bound to the kinase domain of the other. Activation of group I PAKs 
occurs upon binding of small GTPases Cdc42 or Rac to the GBD, relieving the 
inhibitory conformation, and triggering the autophosphorylation at the activation 
loop for subsequent activation of PAK’s kinase activity (Fig. 1-4). Group II PAK 
activation differs from that of Group I PAKs, since the AID of Group II PAKs is 
thought to allosterically modify the constitutively phosphorylated kinase so that it 
becomes active [152]. Both group I and II PAKs are important regulators of 
various biological processes including cell motility, survival, proliferation, 
cytoskeletal organization as well as transcription and translation. Owing to their 
involvement in the above physiological processes, deregulation of functional 
PAKs are implicated in multiple disorders such as cancer, mental retardation, 
allergy, inflammatory and cardiovascular diseases [153]. 
1.6.2.2. PAK1 structure and domains: 
a) Proline-rich regions – Interestingly, PAK1 also interacts with multiple 
substrates depending on unique cellular conditions through its five proline-
rich regions, which contain PXXP (where P and X represent Proline and 
any amino acid, respectively) sites that resemble Src Homology 3 (SH3) 
domain binding motifs. Nck, an adaptor protein that contains one SH2 
domain and three SH3 domains, interacts with the first proline-rich SH3 
domain binding motif (aa 12-18) of PAK1 through its second SH3 domain, 
linking PAK1 and receptor tyrosine kinases (such as IR) in cell 
proliferation and growth [154]. 
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Figure 1.5. PAK structure and activation by small Rho GTPases. Under 
basal conditions PAK exists as a homo-dimer in an auto-inhibitory conformation 
which upon stimulation by growth factors opens up into an active monomeric 
conformation due to binding of activated small Rho GTPases such as Rac1/ 
Cdc42-GTP and auto-phosphorylation of PAK on several serine and threonine 
residues. 
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Similarly, PAK1-Grb2 (Growth factor receptor bound protein 2) adaptor 
protein associate via the second SH3 binding motif of PAK1, mediating the 
coupling of activated Epidermal Growth Factor Receptor (EGFR) and 
PAK1 upon Epidermal Growth Factor (EGF) stimulation in HaCaT cells 
(an immortalized human keratinocyte cell line). In this manner, the 
upstream receptor kinases and downstream PAK1 signaling are linked 
[155]. Moreover, PAK1 binds to the guanine nucleotide exchange factor 
(GEF) for Cdc42, PAK-interactive exchange factor/cloned out of library 
(PIX/COOL) protein through a non-canonical proline-rich region (aa 182-
203).  
b) Autoregulatory fragment – The N-terminal region of PAK1 from amino 
acids 70-149 is termed as the autoregulatory fragment. This region 
consists of three main segments. The first, a p21-binding domain (PBD; 
aa 70-113), includes the minimum sequence for Cdc42/Rac interactive 
binding (CRIB; aa 75-90), essential for the binding of small GTPases. 
Studies using site-directed mutants and truncated fragments revealed the 
sequences required for the high-affinity binding of PAK1 to Cdc42 and 
Rac1 [156-158]. The second region, an autoinhibitory domain (AID; aa 83-
149), acts as an inhibitory switch (IS) and is essential for the trans-
autoinhibition of group I PAKs and the mechanism of inhibition is 
elaborated in the sections 1.6.2.1. [159]. The C-terminal extension of the 
IS region sequesters the critical element, named the kinase inhibitor (KI; 
aa 136-149) segment, which passes through the cleft of the kinase 
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domain, and is required for the “autoinhibited state of PAK”. A segment of 
PAK1 containing the deletion of amino acids 81-87 in the N-terminal 
region of the IS motif, termed as Dimerizatin (Di; aa 81-87) segment, 
exhibits a decreased dimerization [160], implicating an importance of 
trans-dimerization for the inhibition of PAK1 under basal conditions. 
Binding of activated Cdc42 or Rac to the CRIB/PBD region relieves the 
autoinhibited state of the PAK1 dimer by disrupting the intermolecular 
interactions between the IS domain of one monomer and the KD of the 
other (details of the activation process are described in the next section).  
c) Kinase Domain – The kinase domain (aa 249-545) is the catalytically 
active site of PAKs that has the standard, two-lobe structure, and is 
characteristic of all the protein kinases [161]. Interestingly, PAK1 contains 
an intrinsically active kinase domain that catalyzes the serine/threonine 
phosphorylation of its substrates, even in the absence of activators. This 
unique feature advocates the requirement of tight regulation of the active 
site to avoid unwarranted activation of kinase function. Notably, a stretch 
of 30 residues in the large lobe of the kinase domain, designated as the 
“activation loop” (A-loop), contains the critical phosphorylation site 
Threonine 423 (T423), required for the complete activation of PAK1 [162]. 
Moreover, evidence for the existence of the kinase domain in an 
essentially active conformation, even in the absence of T423 
phosphorylation, stems from the studies using kinase-dead mutants 
(K229R) and phosphomimetic (T423E) mutants of PAK1 [163]. At the end 
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of the C-terminus of the Kinase domain, PAK1 has a binding site for Gβγ 
subunit of heterotrimeric G-proteins, which are implicated in the inhibition 
of PAK1 kinase function [164, 165]. 
1.6.2.3. Multistage activation of trans-autoinhibited PAK1: 
PAK1, also referred as PAKα, was first discovered in 1994 in rat brain as a 
protein kinase that binds to the active GTP-bound form of small GTPases Cdc42 
and Rac1 [166, 167]. Originally named PAK65, PAK1 is the most extensively 
studied protein among the PAKs, and is highly homologous to the yeast protein 
Ste20p. The activation of PAK1 is a multistage process that starts with the 
binding of GTP-bound form of Cdc42 or Rac to PAK1’s GBD at the N-terminal 
region, which triggers a series of conformational changes involving disruption of 
the PAK1 dimer and rearrangement of kinase domain into a catalytically 
competent state. Binding of activated Cdc42 or Rac induces conformational 
changes in the GBD and unfolds the IS domain, which results in the dissociation 
of the KI fragment (within the AID) from the catalytically active kinase domain. 
However, PAK1 assumes its fully activated state only after phosphorylation of 
T423 in the activation loop and subsequent phosphorylation of serine residues at 
21, 57, 144, 149, 198 and threonine residue at 212 [160], within the KI region and 
the IS domain, preventing its redimerization into an inactive state [159] The 
significance of the T423 site in the activation of PAK1 comes from the studies 
showing reduced kinase activity of PAK1 carrying the T423A mutation [168]. 
However, signaling downstream of PAK1 that leads to GLUT4 translocation in 
skeletal muscle is still unexplored.  
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1.6.2.4. PAK1 as a signaling kinase:  
Since its discovery in 1994, several cytoskeletal proteins, adaptor proteins, 
Guanine exchange factors (GEF), integrins, kinases as well as phosphatases 
have been identified as PAK1 substrates. PAK1 notably signals downstream to 
pathways involved in cytoskeletal remodeling. For example, the ARP2/3 complex, 
Filamin A, Cortactin, Cofilin and LIMK are some of the major regulators of the 
actin cytoskeletal network that can be regulated by phosphorylation by PAK1 at 
unique serine/threonine residues. These are discussed in detail in Section 1.4. In 
addition to modulating proteins involved in the actin cytoskeletal network, PAK1 
also regulates microtubule dynamics by phosphorylating Tubulin cofactor B 
(TCoB), a cofactor in the assembly of α/β-tubulin heterodimers at Serine residues 
65 and 128. Although, studies using agents that inhibit microtubule 
polymerization such as colchicine suggested against a requirement for 
microtubule-mediated regulation of insulin- or contraction-stimulated glucose 
transport in skeletal muscle [112], more recent findings ( Schisler (2016 FASEB) 
using mice deficient in Carboxyl terminus of HSC70-Interacting Protein (CHIP) 
revealed the significance of microtubule dynamics for insulin-dependent GLUT4 
translocation in skeletal muscle. Decreased GLUT4 translocation was 
accompanied by reduced microtubule polymerization and phosphorylation of 
Stathmin (at Ser16), a microtubule-regulating protein in the CHIP-depleted 
skeletal muscle cells. Intriguingly, PAK1 phosphorylates stathmin at Ser16 and 
regulates its activity in Hep2 cells [169]. Altogether, the above findings point 
towards a potential role of PAK1 in the regulation of microtubule-dependent 
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GLUT4 trafficking in skeletal muscle. Whether decreased phospho-Stathmin 
(S16) levels associate with decreased PAK1 activity or phospho-PAK1 levels in 
the CHIP-depleted skeletal muscle cells remains an open question.  
1.6.2.5. PAK1 as a scaffolding protein: 
Although a vast number of phospho-proteins have been identified as PAK1 
substrates, increasing evidences using kinase-dead mutants of PAK1 indicate a 
kinase- independent scaffolding function for PAK1 in the regulation of 
cytoskeletal reorganization and cell motility [155, 162]. As a scaffold, PAK1 
signals to downstream effectors not by mere transfer of a phosphate group, but 
by creating a platform to allow the tethering of multiple members of a signaling 
pathway into complexes. Towards this, the PAK1-PDK1-AKT signaling pathway 
has been very well studied. Briefly, PAK1 acts a scaffold to facilitate the complex 
formation between AKT and PDK1, which assists in the phosphorylation of AKT 
at T308 by PDK1 [170]. Interestingly, it has been shown that PAK1 is 
phosphorylated and activated by AKT and PDK1, suggesting a positive-feedback 
loop between PAK1 and PDK1/AKT to regulate downstream signaling pathway.  
PP2A is a serine protein phosphatase that is involved in glucose transport and 
glycogen synthesis [171, 172]. PP2A has been shown to associate with and 
subsequently activate the actin-severing protein Cofilin, by dephosphorylating 
Cofilin at Ser3 [173]. Cofilin dephosphorylation has been shown to be a critical 
step involved in the insulin-stimulated Rac1-PAK1 pathway that leads to GLUT4 
translocation in skeletal muscle. PAK1, through its scaffolding function, induces 
PP2A dephosphorylation at Y307 to thereby increase its phosphatase activity 
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[174]. Intriguingly, a study using whole body PAK1 KO mice implicated a 
requirement for PAK1 in the activation of Cofilin in skeletal muscle [132]. Hence, 
one possible explanation for the mechanism of cofilin activation by PAK1 would 
be that PAK1 scaffolds and activates PP2A, leading to the dephosphorylation 
and subsequent activation of cofilin, which in turn regulates the actin remodeling 
process and facilitates the insulin-dependent GLUT4 translocation in skeletal 
muscle. Alternatively, PAK1 might activate cofilin via its signaling function by 
regulating SSH1/ Chronophin (a second potential Cofilin phosphatase) 
phosphatase activity [175]. Further investigation is warranted to fully understand 
this process.  
1.6.2.6. Regulation of PAK1 activity: 
a) Activators of PAK1 – GTP-loaded Small Rho family GTPases such as 
Rac, Cdc42 and TC10 activate PAK1 by binding to the GBD/ CRIB 
domain at the N-terminal region, relieving the autoinhibited homodimer 
conformation, to activate the monomer form (detailed description in earlier 
section 1.6.2.2.). While Cdc42/Rac1 and TC10 function in pancreatic β 
cells and adipocytes, respectively, Rac1 is the only isoform among Rac1, 
Rac2 and Rac3 that regulates both the insulin- and the contraction-
stimulated glucose uptake into skeletal muscle [102, 176]. Besides the 
small Rho family GTPases, Wnt-1 responsive Cdc42 Homolgue (Wrch-1), 
an atypical small Rho GTPase regulated by Wnt-1 signaling, also 
activates PAK1, although the mechanism of activation is not fully 
understood [177]. 
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Moreover, Phosphatidylinositol 4,5-bisphosphate (PIP2), the most 
abundant phosphoinositide at the PM, acts together with Cdc42 to 
synergistically activate PAK1 by binding to the basic region and the GBD 
in the autoinhibitory domain of PAK1, respectively. This recruits PAK1 to 
the membrane ruffles at the plasma membrane [178]. PIP3, the second 
messenger and the phosphorylated form of PIP2, recruits PH domain-
containing proteins and regulates the insulin-stimulated GLUT4 trafficking 
in peripheral tissues. However, the significance of PIP2 in the regulation of 
insulin-stimulated GLUT4 vesicle exocytosis remains elusive.  
The recruitment of PAK1 to membranes also leads to its activation. SH3 
domain-containing adaptor proteins such as Nck/Grb2 bind to the proline-
rich SH3 binding motif of PAK1, recruiting it to the PM and assisting in the 
activation of PAK1 by small Rho GTPases [154]. Moreover, Nck has been 
shown to bind to the activated IRS-1 via its other SH2 binding motif in 
response to insulin. Together, these data might suggest that Nck, by 
activating PAK1, might mediate one of the plausible mechanisms to 
couple the upstream insulin signaling events involving the cell surface 
receptors and its downstream effectors, required for GLUT4 exocytosis. 
b) Negative regulators of PAK1 – Since uncontrolled PAK1 activation 
might result in deleterious metabolic effects, mechanisms to ensure 
appropriate PAK1 activation are essential. Recent evidence from 
Takenawa et al revealed that Skeletal muscle and kidney-enriched inositol 
polyphosphate phosphatase (SKIP), a protein already implicated in insulin 
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signaling in skeletal muscle, negatively regulates PAK1 by blocking its 
scaffolding function in regulating PDK1-AKT2 mediated insulin-stimulated 
glucose uptake. 
1.7. ROLE OF PAK1 IN THE MAINTENANCE OF WHOLE BODY GLUCOSE 
HOMEOSTASIS 
Whole body PAK1 KO mice exhibited glucose intolerance with impaired insulin 
sensitivity, underpinned by defects in insulin-stimulated GLUT4 vesicle 
translocation and cofilin dephosphorylation in skeletal muscle. As a whole-body 
KO model, the PAK1 KO mice also exhibited defects in glucose-induced insulin 
secretion. In an independent study of the whole body PAK1 KO mice, a 
significance for PAK1 in mediating the cross talk between insulin and Wnt 
signaling pathways on gut and brain proglucagon expression was raised, a route 
completely different from pancreas and skeletal muscle. The Insulin Resistance 
Atherosclerosis Study (IRAS) and Genome-Wide Association Study (GWAS) 
have localized susceptibility genes, including PAK1, to Chromosome 11, a 
notable diabetes locus. Substantiating this, PAK1 protein levels were reduced in 
human T2D islets, implicating the significance of PAK1 in the maintenance of 
metabolic homeostasis.  
Insulin and contraction both stimulate the translocation of perinuclear GSVs and 
their fusion to the sarcolemma and T-tubules, facilitating the entry of glucose into 
the skeletal muscle. Interestingly, both insulin and contraction induce the 
activation of PAK1 in skeletal muscle. Moreover, multiple studies using muscle 
specific inducible Rac1 KO mice have revealed the requirement of Rac1 in both 
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insulin and contraction-stimulated glucose uptake into mature skeletal muscle. 
However, the activation of PAK1, a known downstream target of Rac1 in other 
cell types, has yet to be placed in the signaling cascade emanating from Rac1 in 
muscle cells. 
1.8. RATIONALE AND CENTRAL HYPOTHESIS 
The rationale for studying the role of PAK1 in skeletal muscle insulin sensitivity is 
that delineating the molecular mechanisms of PAK1 signaling pathway in skeletal 
muscle glucose uptake will provide us with potential novel therapeutic targets for 
interventions to treat or even prevent T2D. The central hypothesis of my 
dissertation is formulated based on published literature including the following 
evidence: 1) Whole body PAK1 KO mice exhibited glucose intolerance with 
impaired insulin sensitivity; 2) PAK1 protein levels and function were reduced in 
metabolically-relevant human T2D tissues, implicating the significance of PAK1 
in the maintenance of metabolic homeostasis. Thus my central hypothesis is that, 
PAK1 exists in an insulin signaling cascade that triggers F-actin remodeling to 
facilitate GLUT4 vesicle translocation to the cell surface, leading to glucose 
uptake into the skeletal muscle and clearance of excess circulating blood glucose. 
To test this hypothesis I pursued two Specific Aims: 1) Determine the role and 
requirement of PAK1 signaling in insulin-dependent glucose uptake in skeletal 
muscle cells; and 2) Delineate the PAK1 signaling cascade that evokes F-actin 
remodeling required for the insulin-stimulated GLUT4 translocation in skeletal 
muscle cells. 
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CHAPTER 2 
SIGNALING OF THE P21-ACTIVATED KINASE (PAK1) COORDINATES 
INSULIN-STIMULATED ACTIN REMODELING AND GLUCOSE UPTAKE IN 
SKELETAL MUSCLE CELLS 
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2.1. SYNOPSIS 
Skeletal muscle accounts for ~80% of postprandial glucose clearance, and 
skeletal muscle glucose clearance is crucial for maintaining insulin sensitivity and 
euglycemia. Insulin-stimulated glucose clearance/uptake entails recruitment of 
glucose transporter 4 (GLUT4) to the plasma membrane (PM) in a process that 
requires cortical F-actin remodeling; this process is dysregulated in Type 2 
Diabetes. Recent studies have implicated PAK1 as a required element in GLUT4 
recruitment in mouse skeletal muscle in vivo, although its underlying mechanism 
of action and requirement in glucose uptake remains undetermined. Toward this, 
we have employed the PAK1 inhibitor, IPA3, in studies using L6-GLUT4-myc 
muscle cells. IPA3 fully ablated insulin-stimulated GLUT4 translocation to the PM, 
corroborating the observation of ablated insulin-stimulated GLUT4 accumulation 
in the PM of skeletal muscle from PAK1-/- knockout mice. IPA3-treatment also 
abolished insulin-stimulated glucose uptake into skeletal myotubes. 
Mechanistically, live-cell imaging of myoblasts expressing the F-actin biosensor 
LifeAct-GFP treated with IPA3 showed blunting of the normal insulin-induced 
cortical actin remodeling. This blunting was underpinned by a loss of normal 
insulin-stimulated cofilin dephosphorylation in IPA3-treated myoblasts. These 
findings expand upon the existing model of actin remodeling in glucose uptake, 
by placing insulin-stimulated PAK1 signaling as a required upstream step to 
facilitate actin remodeling and subsequent cofilin dephosphorylation. Active, 
dephosphorylated cofilin then provides the G-actin substrate for continued F-
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actin remodeling to facilitate GLUT4 vesicle translocation for glucose uptake into 
the skeletal muscle cell.  
2.2. INTRODUCTION 
Insulin maintains the glucose homeostasis of the body by mobilizing insulin-
responsive glucose transporter 4 (GLUT4)-containing vesicles from intracellular 
compartments to the plasma membrane (PM) of muscle and adipose cells, 
facilitating glucose uptake into these tissues [179-181].  Defects and/or 
deficiencies in insulin-stimulated glucose uptake by these peripheral tissues 
promote the development of peripheral insulin resistance and pre-diabetes [182].  
Skeletal muscle glucose uptake accounts for ~80% of all insulin-stimulated 
uptake [183].  Under normal insulin-sensitive conditions, circulating insulin binds 
to the insulin receptor present on the extracellular surface of the skeletal muscle 
cell to initiate an intracellular signaling cascade which bifurcates downstream of 
phosphatidylinositol 3-kinase (PI3K) into at least two parallel pathways that lead 
to GLUT4 vesicle translocation, facilitating glucose uptake into the muscle cell 
[184].  Though the first pathway involving PI3K-Akt-AS160-Rab GTPase leading 
to GLUT4 vesicle translocation is well-studied, the second insulin-signaling arm 
involving PI3K-Rac1 and actin remodeling to GLUT4 vesicle mobilization in 
skeletal muscle remains incompletely characterized.  
Rac1 is a small Rho family GTPase which is typically involved in the regulation of 
cytoskeletal reorganization and vesicular traffic in most cell types [185].  Growing 
evidence supports the involvement of Rac1 in insulin-induced GLUT4 vesicle 
translocation to the cell surface, both in cultured L6 muscle cells and mature 
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primary skeletal muscle [186].  Knockdown or inhibition of Rac1 activity ablates 
GLUT4 translocation and subsequent glucose uptake [176].  Rac1 mediates this 
process by inducing cortical F-actin remodeling, which involves the recruitment of 
actin regulatory proteins such as cofilin and Arp2/3 to the actin filaments in 
skeletal muscle cells [121]. Additionally, Rac1 signals to p21-activated kinase 1 
(PAK1) in skeletal muscle and facilitates its phosphorylation in response to 
insulin [187]. Insulin-stimulated PAK1 activation was decreased in human 
skeletal muscle of both acute (intralipid infusion) and chronic (obesity and Type 2 
diabetes) insulin resistant states, implicating PAK1 as a required element in 
maintaining euglycemia and insulin sensitivity. However, the connections 
between PAK1, Rac1 and cortical F-actin remodeling to mediate insulin-
dependent GLUT4 movement to the cell surface have yet to be established.  
Several studies in mice depleted of PAK1 (whole-body PAK1-/- knockout) support 
the requirement for PAK1 in the maintenance of glucose homeostasis in vivo, 
linked to its actions in islets and skeletal muscle [132].  Although PAK1 function 
in islets appears to be linked to Cdc42 [188, 189], its role in skeletal muscle is 
predicted to be linked instead to Rac1, given that Rac1 but not Cdc42 has been 
shown to participate in glucose uptake.  However, given the reported 
requirements for PAK1 in heart tissue, two cell types of the islet (α- and β-cells) 
and intestinal cells [190], the metabolic derangement of the PAK1 KO mouse and 
the role of PAK1 in skeletal muscle has remained unresolved.  In addition, PAK1 
serves two roles, one as a kinase in signaling actions, and another as a 
scaffolding protein [162]. Moreover, it is unknown whether PAK1’s signaling or 
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scaffolding functions, or both, are required for GLUT4 vesicle translocation and 
glucose uptake in skeletal muscle for the regulation of whole-body glucose levels.  
In the current study we tested the hypothesis that PAK1 signaling is required for 
insulin-stimulated GLUT4 vesicle translocation to the cell surface by contributing 
to cortical actin remodeling in skeletal muscle cells. Towards this end, we 
employed an inhibitor of PAK signaling, IPA3, to distinguish PAK1’s requirement 
for signaling from that of scaffolding. IPA3 is a selective inhibitor of the group I 
PAK isoforms; another PAK inhibitor, PF-3758309, acts on both group I and II 
PAKs. Skeletal muscle and L6-GLUT4myc clonal muscle cells were used, as 
both showed identical expression of the Group 1 PAK isoforms, of which only the 
PAK1 isoform was found to be of significance to insulin-stimulated GLUT4 
vesicle translocation. Inhibition of PAK1 signaling function completely ablated 
insulin-dependent GLUT4 translocation and glucose uptake in L6-GLUT4myc 
muscle cells. Mechanistically, IPA3 blunted the insulin-induced dynamic 
rearrangement of cortical F-actin in L6-GLUT4myc myoblasts. We further 
demonstrate that PAK1 signals to dephosphorylate cofilin, in a manner 
independent of LIM kinase, revealing an unusual signaling axis for actin 
remodeling in skeletal muscle cells.  
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2.3. MATERIALS AND METHODS 
2.3.1. Materials 
Rat L6 GLUT4-myc skeletal muscle cells expressing c-myc tagged GLUT4 
protein were developed as described. MEMα medium was purchased from 
Invitrogen (Carlsbad, CA).  Porcine insulin, rabbit anti-Actin antibody and 2-
Deoxyglucose were purchased from Sigma-Aldrich (St. Louis, MO). The LifeAct-
GFP plasmid was kindly provided by Dr. Louis Philipson (University of Chicago, 
IL [191]), and the GFP-hPID and GFP-hPID-L107F plasmids were a gift from Dr. 
Jonathan Chernoff (Fox Chase Cancer Center, PA [192]). An inhibitor of the 
activation of group I PAKs (IPA3), phospho-PAK1T423 and mouse anti-p-cofilin 
antibody were purchased from Santa Cruz Biotech (Santa Cruz, CA). Phospho-
PAK1T423/phospho-PAK2T402, PAK1, PAK2, PAK3, cofilin, phospho-
ERK1/2T202/Y204 and ERK1/2 antibodies were obtained from Cell Signaling 
(Danvers, MA).  Fetal bovine serum and goat anti-mouse horseradish peroxidase 
secondary antibody were obtained from Thermo-Fisher Scientific (Rockford, IL). 
Goat anti-rabbit horseradish peroxidase secondary antibody was purchased from 
Bio-Rad (Hercules, CA). Enhanced chemiluminescence reagent (ECL), ECL 
prime and SuperSignal™ Femto were purchased from GE Healthcare 
(Piscataway, NJ) and Pierce (Rockford, IL), respectively.   
2.3.2. Cell culture  
L6-GLUT4myc myoblasts were grown as monolayers in MEM-α medium 
supplemented with 10% fetal bovine serum and 1% (v/v) antibiotic-antimycotic 
solution. L6-GLUT4-myc myoblasts at 40% confluency were differentiated into 
	 55 
myotubes by incubation in MEM-α medium containing 2% fetal bovine serum. For 
all the studies involving IPA3, L6-GLUT4-myc myoblasts (~ 90% confluency) 
were pre-incubated in serum-free medium for 3 hr with IPA3 added for the times 
indicated in the figures just prior to insulin stimulation (100 nM). Cells were 
harvested in 1% NP-40 lysis buffer containing 25 mM HEPES, pH 7.4, 1% 
Nonidet P-40, 10% glycerol, 50 mM sodium fluoride, 10 mM sodium 
pyrophosphate, 137 mM NaCl, 1 mM sodium vanadate, 1 mM 
phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 1 µg/ml pepstatin, 5 µg/ml 
leupeptin and cleared of insoluble material by centrifugation at 13,000 x g for 10 
min at 40C. Supernatant was used for immunoblot analyses.  Cells were 
transfected with plasmid DNA using Effectene transfection reagent (Qiagen, 
Valencia, CA), Lipofectamine 2000 (LifeTechnologies, Grand Island, NY) or with 
siRNA oligonucleotides using Jet Prime transfection reagent according to the 
manufacturer’s protocol (Polyplus transfection, NY, USA) as recently described 
[193]. siRNA oligonucleotide sequences used: siPAK2 sense 5'-
ggucugucaucgacccuautt-3' and antisense 5'-auagggucgaugacagacctt-3'; 
siControl sense 5'-uaaggcuaugaagagauactt-3' and antisense 5'-
guaucucuucauagccuuatt-3', obtained from Qiagen. 
2.3.3. RNA isolation and qRT-PCR 
RNA was isolated from islets using the RNAeasy Fibrous Tissue Mini kit (Qiagen, 
Valencia, CA) and reverse-transcribed to cDNA using the Superscript First strand 
synthesis system (Invitrogen, Carlsbad, CA). PCR was performed using Biomix 
red for 30 cycles: 94°C for 1 min, 56°C for 1 min, and 71°C for 1 min, with a final 
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10-min elongation at 71°C and PCR products were visualized on 2% agarose gel.  
Primers used for the detection of PAK1 (forward: 5-tgtctgagaccccagcagta and 
reverse: 5’-cccgagttggagtaacagga), PAK2 (forward 5-aacaccagcactgaacacca and 
reverse 5’-cttggcaccactgtcaacat) PAK3 (forward 5-gcagcacatcagtcgaatacca and 
reverse 5’-tttatttggtgcagctggt) and GAPDH (5′-atggtgaaggtcggtgtgaacg and 
reverse 5′-gttgtcatggatgaccttggcc) were obtained from IDT (Coralville, IA).  The 
qRT-PCR reaction was performed using CFX Connect Real-Time system (Bio-
Rad, Hercules, CA) and amplifications were done using the Platinum SYBR 
Green qPCR SuperMix-UDG (Invitrogen, Carlsbad, CA). The thermal cycling 
conditions for the reaction were as follows: 50°C for 2-min hold (UDG incubation), 
95°C for 2-min hold, 40 cycles of 95°C for 15 s, and 60°C for 30 s. PCR products 
were visualized on 2% agarose gels. Relative quantification in gene expression 
levels were quantified using the 2 -ΔCt method where relative mRNA levels of 
PAK1, 2 and 3 reported are normalized to GAPDH. 
2.3.4.  Live-cell imaging 
L6-GLUT4myc myoblasts were seeded on MatTek glass bottom culture dishes at 
a density of 300,000 cells per 35 mm dish.  At ~40% confluency cells were 
transfected with LifeAct-GFP plasmid using Effectene transfection reagent 
(Qiagen, Valencia, CA).  Live-cell imaging was performed on cells 48 hr post-
transfection.  Briefly, on the day of the experiment the cells were pre-incubated in 
serum-free KRPH buffer (120 mM NaCl, 2.5 mM KCl, 20 mM HEPES, 1.2 mM 
MgSO4, 1 mM NaH2PO4, and 2 mM CaCl2) supplemented with 5 mM D-glucose 
for 3 h, then IPA3 or vehicle (DMSO) added for 50 min.  LifeAct-GFP imaging 
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was performed on a custom spinning-disk confocal microscope with a heated 60x 
Plan Apo Lambda 1.4 NA objective lens and sample chamber with temperature, 
humidity and CO2 regulation built around a CSU-10 spinning disk confocal head 
(Yokogawa) which is controlled by NIS Elements AR v 4.10 (Nikon Instruments).  
Images were captured every 60 sec starting 1 min before the addition of insulin 
and continued through until 10 min after the addition of insulin. Movies of each 
condition are shown as Supplemental data movies 1-4.  
2.3.5. Cell surface GLUT4myc detection 
Cell surface GLUT4myc detection was performed as described earlier [194].  
Briefly, L6-GLUT4-myc myoblasts or myotubes were pre-incubated in serum-free 
medium containing IPA3 (25 µM) or vehicle (DMSO) for 40 min followed by 
insulin stimulation (100 nM for 20 min), all at 37oC.  Cells were then fixed with 4% 
paraformaldehyde in PBS for 20 min at room temperature (RT), blocked in 
Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln, NE) for 1 h at RT and 
incubated with mouse anti-Myc antibody overnight at 4oC. Cells were extensively 
washed with PBS and then incubated with infrared (IR)-conjugated secondary 
antibody for 1 h at RT. Immunofluorescence intensity of the IR-conjugated 
secondary antibody was quantified using the LiCor infrared imaging system (LI-
COR Biosciences, Lincoln, NE) and data normalized to SYTO 60 (Invitrogen, 
Carlsbad, CA) , a red fluorescent nucleic acid stain.  
2.3.6.  2-Deoxyglucose uptake assay 
The 2-deoxyglucose uptake assay was performed as described [195].  Briefly, L6 
myotubes were pre-incubated in serum-free FCB buffer (125 mM NaCl, 5 mM 
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KCl, 1.8 mM CaCl2, 2.6 mM MgSO4, 25 mM HEPES, 2 mM pyruvate, 2% BSA) 
for 30 min, IPA3 or vehicle added for 40 min, and then stimulated with insulin for 
20 min.  Glucose uptake was initiated by the addition of 2-deoxy[1,2,-3H] glucose 
(Perkin Elmer, Waltham, MA) and uptake terminated after 5 min by four quick 
washes with ice cold PBS followed by addition of 250 µl of 1N NaOH for 
quantitation of [3H] using liquid scintillation.  Data were normalized for variability 
in protein concentration, as determined by Bradford assay. 
2.3.7.  Immunoblotting 
Proteins in cell lysates were resolved using 10-12% SDS-PAGE and transferred 
to PVDF membranes for immunoblotting.  Immunoreactive bands were visualized 
using ECL, ECL Prime, or Supersignal Femto reagents and imaged using a 
BioRad Chemi-Doc gel documentation system.  Phosphorylated and total 
ERK1/2 proteins were visualized using goat anti-mouse 680 and anti-rabbit 800 
simultaneously for LiCor imaging. 
2.3.8. Statistical analysis 
All data were expressed as the average ± SE using Students t-test. Time course 
and dose response data were evaluated with one-way ANOVA and a Tukey post-
hoc test using GraphPad PrismTM (La Jolla, CA).
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2.4. RESULTS 
 2.4.1. PAK expression and inhibition by IPA3 in skeletal muscle cells  
To determine if the defects in insulin-stimulated GLUT4 accumulation at the cell 
surface in the PAK1 KO mice were related to PAK1 signaling, we employed IPA3, 
an allosteric inhibitor of PAK kinase activation and signaling activity that is 
selectively initiated by the small GTPases Rac1 and Cdc42 [196, 197]. IPA3 
binds covalently to the PAK1 regulatory domain and prevents binding to these 
upstream activators, although pre-activated PAK is not inhibited by IPA3. IPA3 is 
capable of inhibiting all PAK isoforms of the Group 1 family (includes PAKs 1-3), 
therefore the expression of all three of these isoforms in skeletal muscle was 
evaluated using immunoblotting and quantitative real-time PCR (qRT-PCR). Of 
the three existing isoforms, only PAK1 and PAK2 were found in skeletal muscle 
of C57BL6 mice (Fig. 1A-B), and this pattern was recapitulated by L6-GLUT4-
myc myoblasts. PAK1 and PAK2 migrate at distinct molecular weights on SDS-
PAGE (68 and 61 kDa, respectively), and immunoblotting using a phospho-
specific PAK1/2T423/402 antibody showed that PAK1 displays substantial insulin-
stimulated phosphorylation/activation (versus basal=1.0, insulin-stimulated=2.0 ± 
0.3, p<0.05) within 10 min (Fig. 1C). In fewer than half of all experiments using 
this antibody, PAK2 showed low levels of phosphorylation. By contrast, PAK1 
consistently displayed a high level of activation in response to insulin, further 
confirmed using a PAK1T423 selective phospho-specific antibody in Fig. 1D 
(versus basal=1.0, insulin-stimulated=1.6 ± 0.1, p<0.05). 
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Figure 2.1. Group I PAK isoforms in skeletal muscle and L6-GLUT4-myc 
cells. Hindlimb muscle from wild-type (WT) mice was homogenized and 
analyzed for the three Group I PAK members PAK1, 2 and 3 for A) mRNA 
content using qRT-PCR (normalized to GAPDH) from three sets of tissues, and 
B) protein expression.  L6-GLUT4-myc myoblasts were assessed similarly for 
protein expression of all three Group I PAKs; mouse brain lysates served as 
control (CTRL) as they co-express all three isoforms. Vertical black lines denote 
splicing of lanes from the PAK1, PAK2, PAK3 and actin immunoblots. C) Lysate 
proteins from L6-GLUT4-myc myoblast cells left unstimulated or insulin-
stimulated (100 nM, 10 min) were resolved by 12% SDS-PAGE for immunoblot 
detection of phosphorylated- and total- PAK1 and PAK2 proteins and D) 
specifically for phosphorylated PAK1. Data are representative of three 
independent experiments, with average insulin-stimulated p-PAK1/total PAK1 
ratios shown below the blots, normalized to basal=1.0 for each experiment. 
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We next optimized the dosage and time-dependence of IPA3 action in myoblasts, 
based upon prior experimentation using IPA3.  IPA3 provoked a >60% inhibition 
of insulin-stimulated PAK1 phosphorylation at 25 and 30 µM (Fig. 2A). At 25 µM, 
inhibition of PAK1 activation was consistently achieved within 60 min (Fig. 2B). 
No PAK2 phosphorylation was detected in any of these experiments. IPA3 
treatment at the most effective time and dose was without impact upon insulin-
dependent Akt phosphorylation (Fig. 2C), reminiscent to the lack of impact on Akt 
phosphorylation displayed by skeletal muscle of PAK1 KO mice. Therefore, 25 
µM IPA3 treatment for 60 min was used in subsequent experiments.  
 2.4.2. Insulin-stimulated PAK1 phosphorylation is essential for 
GLUT4 vesicle translocation and glucose uptake into skeletal 
muscle cells 
We next examined the effect of IPA3 on insulin-stimulated GLUT4 vesicle 
exocytosis and glucose uptake. Insulin stimulated a 170% increase in GLUT4 at 
the cell surface in myoblasts treated with vehicle alone (DMSO), and IPA3 
treatment abrogated this effect of insulin (Fig. 3A). IPA3 did not exert a negative 
impact upon basal/unstimulated levels of GLUT4 (versus vehicle control=1.0, 
IPA3=1.1 ± 0.1, p>0.05). Glucose uptake was measured in myotubes, since at 
this stage the contribution of the housekeeping glucose transporter GLUT1 to 
glucose uptake is minimal. Consistent with the reduction in GLUT4 translocation, 
IPA3 treatment markedly reduced insulin-stimulated glucose uptake into L6 
myotubes (Fig. 3B). In another approach, myoblasts were transfected to express  
	 62 
  Insulin:  
  IPA3 (min):  
  IB: p-PAK1/2  
  IB: PAK1  
  IB: Actin  
++ + +- - - -
0 20 30 60
A
1
0
2
0
   p
-P
AK
1/
 P
AK
1 
IPA3 (     ):μM 20 3025
*
*
B
Figure 2
1
0
2
   p
-P
AK
1/
 P
AK
1 
0IPA3 (min): 20 6030
*
*
*
3
  IB: p-AKT  
  IB: AKT  
  IB: Actin  
IPA3 (min):
  Insulin:  +- +-
- - + +
C
0
5   p
-A
KT
/ A
KT
 
IPA3:
  Insulin:  + +
- +
  Insulin:  + + + +
  Insulin:  + + + +
20
10
15
	
  Insulin:  
  IPA3 (min):  
  IB: p-PAK1/2  
  IB: PAK1  
  IB: Actin  
++ + +- - - -
0 20 30 60
A
1
0
2
0
   p
-P
AK
1/
 P
AK
1 
IPA3 (     ):μM 20 3025
*
*
B
Figure 2
1
0
2
   p
-P
AK
1/
 P
AK
1 
0IPA3 (min): 20 6030
*
*
*
3
  IB: p-AKT  
  IB: AKT  
  IB: Actin  
IPA3 (min):
  Insulin:  +- +-
- - + +
C
0
5   p
-A
KT
/ A
KT
 
IPA3:
  Insulin:  + +
- +
  Insulin:  + + + +
  Insulin:  + + + +
20
10
15
 
Figure 2.2. IPA3 inhibits insulin-stimulated PAK1 phosphorylation in L6-
GLUT4- yc myoblasts.  A) Dose-optimization: L6 myoblasts were pretreated 
with IPA3 at 20, 25 or 30 µM for 10 min followed by insulin stimulation for an 
additional 10 min.  Detergent cleared cell lysates were prepared and proteins 
resolved by SDS-PAGE for immunoblot and optical density scanning quantitation 
for p-PAK1 relative to total PAK1 (in arbitrary units).  B) Time course: L6 
myoblasts were treated with 25 µM IPA3 for 0, 20, 40 or 60 min, with insulin 
added in the final 10 min (100 nM).  Cell lysates were immunoblotted for p-PAK1 
and PAK1 and quantified as in A) above. (C) p-AKT and total AKT were 
immunoblotted and quantified from cells treated with vehicle (-) or 25 µM IPA3 for 
60 min as described in A) above. Bar graphs represent the average ± SE of three 
independent cell passages; *p<0.05. The vertical black line denotes splicing of 
lanes from within the same gel exposure. 
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the PAK1 auto-inhibitory domain (PID), a known dominant-negative for PAK1  
signaling actions. Indeed, PID-expressing myoblasts showed attenuated insulin-
stimulated GLUT4 translocation to the cell surface, relative to that of cells 
expressing the non-inhibitory mutant PID-L107F (Fig. 3C). PID had no negative 
impact upon basal levels of surface GLUT4 (versus L107F control=1.0, PID=1.2 
± 0.1, p>0.05). Since IPA3 also has the capacity to inhibit PAK2, we tested the 
effect of PAK2 depletion in L6 myoblasts. Transfection with siPAK2 
oligonucleotides achieved 75% PAK2 knockdown relative to non-targeting control 
oligonucleotides (Fig. 3D), yet this was without effect upon insulin-stimulated 
GLUT4 translocation (Fig. 3E). Combined with evidence showing skeletal muscle 
PAK1 KO to exhibit attenuated insulin-stimulated GLUT4 translocation [198], 
these data suggest that PAK1 signaling is required for insulin-stimulated GLUT4 
vesicle exocytosis in L6 myoblasts, revealing a selective importance for PAK1 in 
this process.  
 2.4.3. PAK1 signaling is required for insulin-induced F-actin 
remodeling in skeletal myoblasts 
Since PAK1 inhibition by IPA3 did not affect Akt phosphorylation, we tested the 
possibility that PAK1 contributes to the insulin-signaling arm involving PI3K-Rac1 
and actin remodeling. Actin remodeling is a prerequisite for GLUT4 vesicle 
translocation and glucose uptake into L6 myoblasts [199] and mature skeletal 
muscle [114]. PAK1 is known to impact actin remodeling in other cell types,  
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Figure 2.3.  PAK1 activity is essential for insulin stimulated GLUT4 vesicle 
translocation and glucose uptake in skeletal muscle cells.  A) Surface 
GLUT4: L6-GLUT4-myc myoblasts treated with IPA3 or vehicle (DMSO) were 
stimulated with insulin (100 nM, 20 min) for LiCor analyses of surface GLUT4 
levels.  Immunofluorescent intensity of cell surface GLUT4 was normalized to 
nucleic acid staining dye, Syto 60, and data displayed as the fold-stimulation of 
insulin-stimulated surface GLUT4, relative to unstimulated/basal level. Bars 
represent the average ± SE of four independent cell passages; *p<0.05, vs 
vehicle (-) treated cells. B) Glucose uptake: L6-GLUT4-myc myotubes were used 
for 2-deoxyglucose uptake assays as described in Methods.  Data represent the 
average (± SE) fold stimulation in response to insulin relative to basal level 
glucose uptake, in at least three independent passages of cells; *p<0.05, vs 
vehicle (-) treated cells.  C) L6-GLUT4-myc myoblasts were transfected to 
express GFP-tagged PAK1 inhibitory domain (PID) or non-inhibitory control (PID-
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L107F) and assessed for fold stimulation of insulin-stimulated GLUT4 as 
described in A) above. Bars represent the average ± SE of three independent 
cell passages; *p<0.05, vs PID-L107F-expressing cells.  D) Myoblasts were 
transfected with control (siCon) or PAK2-selective (siPAK2) siRNA 
oligonucleotides, normalized to actin (arbitrary units). Bars represent the average 
± SE of three independent cell passages; *p<0.05, vs siCon.  E) GLUT4 vesicle 
translocation assays from siPAK2 or control (siCon) transfected cells, as 
described in A) above.  No significant differences were detected in four 
independent experiments. Experiment for Figure 2C was done by our 
collaborator Tim T. Chiu. 
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either by inducing F-actin formation/assembly or reducing F-actin in a cell type-
specific manner.  All studies to date have used fixed-cell imaging to study this 
process, with the inherent caveat that basal and insulin-stimulated images derive 
from different cells. Instead, we sought to capture the real-time changes in actin 
polymerization in single cells using live-cell imaging of L6 myoblasts harboring 
the LifeAct-GFP biosensor.  LifeAct is a 17 residue peptide from the actin binding 
protein Abp140 linked to the N-terminus of GFP to form LifeAct-GFP, which has 
been shown to bind specifically to F-actin in live cells without adversely affecting 
F-actin dynamics. L6 myoblasts transfected to express LifeAct-GFP exhibited F-
actin remodeling within minutes of insulin stimulation, as can be viewed in real-
time movies (Supplemental movies 1-4), with still images captured at the end of 
the 10 min period (Fig. 4); remodeling is visualized as membrane ruffling (see 
regions denoted by arrows). Notably, IPA3 treatment completely blocked all 
insulin-induced F-actin remodeling across the entire imaging period in all 
independent movies captured. These experiments are the first to demonstrate 
the time-lapse events of insulin-stimulated actin remodeling in skeletal muscle 
cells, wherein PAK1 plays an essential role in the process. 
 2.4.4. Insulin-stimulated PAK1 signaling in L6 myoblasts 
We next questioned whether PAK1 signaling to evoke F-actin remodeling 
occurred via a canonical or non-canonical route.  The canonical pathway from 
PAK1 to evoke cofilin phosphorylation is through activation of LIM kinase 
(LIMK1/2) in other cell types. Incongruent with this, LIMK knockdown in L6  
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Figure 2.4.  Insulin-induced PAK1 signaling is important for insulin-induced 
F-actin remodeling in L6-GLUT4-myc myoblasts.  L6-GLUT4-myc myoblasts 
were transfected to express the LifeAct-GFP biosensor for live-cell imaging of F-
actin remodeling.  Myoblasts treated with vehicle or IPA3 were imaged using an 
custom spinning-disk confocal microscope and captured every min from 1 min 
prior insulin addition and on through to 10 min after insulin stimulation (100 nM).  
Arrows denote regions of ruffling.  Images represent still images taken from at 
least four cell movies of each treatment condition conducted using four 
independent passages of cells.  
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myoblasts failed to substantially affect cofilin phosphorylation.  Hence, IPA3 was 
used to evaluate this canonical pathway, serving as an alternative to depleting 
PAK1 which otherwise also impedes its scaffolding function.  Insulin stimulation 
triggered a > 2-fold increase in p-PAK1 activation, and this was inhibited by IPA3 
(Fig. 5A); IPA3 was without impact upon basal activation (versus vehicle=1.0, 
IPA3= 1.0 ± 0.2, p>0.05), as seen in Fig. 2B.  In the same cell lysates, insulin 
stimulated LIMK phosphorylation by ~2-fold; however, IPA3 failed to inhibit this 
activation (Fig. 5B). IPA3-treated lysates showed slightly higher pLIMK levels 
(versus basal vehicle of 0.5 ± 0.03, IPA3 = 1.0 ± 0.07), although since insulin-
stimulated pLIMK were similarly altered, the fold activation level was comparable 
to that of vehicle-treated cells. Issues with pLIMK and LIMK antibodies required 
that dual gels be used, one for LIMK and the other for pLIMK immunoblotting, 
with each normalized for deviations in protein loading to actin, and then the 
pLIMK/total LIMK calculated. The pLIMK antibody recognized multiple non-
specific bands, and the true pLIMK bands were discerned by paired migration 
against the correct band in stimulated HUVEC cells as recommended by the 
manufacturer. As shown previously, and opposite to the canonical pathway, 
insulin stimulation decreased p-cofilin levels to ~50% of that from unstimulated 
cells. Importantly, IPA3-treated myoblasts showed blunted insulin-stimulated 
cofilin dephosphorylation (Fig. 5C).  Consistent with its lack of effect upon 
surface GLUT4 or glucose uptake, IPA3 was without effect upon basal levels of 
cofilin phosphorylation (versus control=1.0, IPA3=0.9 ± 0.1, p>0.05). Insulin-
induced phosphorylation of ERK served as an unrelated pathway control for the  
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Figure 2.5.  PAK1 signaling is required selectively for insulin-stimulated 
cofilin de-phosphorylation in L6-GLUT4-myc myoblasts.  L6-GLUT4-myc 
myoblasts treated with vehicle or IPA3 were stimulated with insulin (100 nM, 10 
min) and resulting detergent cleared cell lysates resolved on 12% SDS-PAGE for 
simultaneous immunoblot detection of A) p-PAK1 and total PAK1, B) p-LIMK and 
total LIMK C) p-cofilin and total cofilin, and D) p-ERK and total ERK. Optical 
density scanning was used for quantification, with bar graphs representing the 
average ± SE of fold changes in activations evaluated in four independent 
experiments; *p<0.05. Vertical black lines denote splicing of lanes from within the 
same gel exposure within each figure panel. 
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PAK-specific effects of IPA3, and to demonstrate that the cells were 
appropriately responsive to insulin (Fig. 5D). Taken together, these findings  
highlight the importance of PAK1 signaling for cofilin de-phosphorylation, which 
proceeds through a non-canonical, LIMK-independent pathway. 
2.5. DISCUSSION 
PAK1 KO mice exhibit peripheral insulin resistance [132].  However, since PAK1 
is known to function both as a scaffolding protein as well as a signaling protein, 
its ablation in the PAK1 KO mouse model left elucidation of its specific function(s) 
in regulating insulin sensitivity unresolved. Moreover, this whole body knockout 
model of PAK1 precluded assigning its mode of action directly to skeletal muscle. 
Here, we show that insulin-stimulated PAK1 activation is an integral step in the 
signaling cascade that enables actin remodeling and GLUT4 vesicle 
translocation to stimulate glucose uptake into skeletal muscle cells.  Showing for 
the first time the kinetics of insulin-stimulated actin remodeling in live skeletal 
muscle cells by time-lapse imaging using the F-actin biosensor LifeAct-GFP, we 
reveal that PAK1 activation is required to display this actin remodeling. Since 
IPA3-mediated PAK1 inhibition failed to impair Akt phosphorylation but did impair 
actin remodeling, PAK1 signaling is likely required in the Akt-independent 
PI3K→Rac1 signaling cascade of insulin action. Prior work shows that insulin-
stimulated cofilin dephosphorylation is required for GLUT4 translocation [121]; 
our data fully recapitulate this work. Mechanistically, our data expand upon this to 
show that IPA3-mediated inhibition of p-PAK1 abrogates the dephosphorylation 
of cofilin, a finding incongruent with the canonical, stimulus-induced p-PAK1→p-
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LIMK→p-cofilin response. Moreover, cofilin dephosphorylation occurred in a 
manner independent of LIMK, suggesting that PAK1 contributes to actin 
remodeling via a non-canonical pathway.  
The requirement for PAK1 signaling to evoke the dephosphorylation of cofilin is 
unusual, only otherwise reported to occur in the MCF-7 cells [200].  PAK1 signals 
to numerous substrates in a variety of cell types [201], one of which is LIMK, 
which in turn leads to the phosphorylation (inactivation) of cofilin to regulate the 
actin cytoskeletal dynamics. In contrast, insulin-stimulated actin remodeling in 
skeletal muscle cells involves cofilin dephosphorylation. The model drawn from 
these findings proposes that GLUT4 vesicle translocation and fusion requires 
active cycling or ‘remodeling’ of actin.  Our live-cell imaging demonstrates this 
dynamic cycling to occur in response to insulin, and that PAK1 signaling is 
required to facilitate the cycling.  Supporting this concept in the context of cofilin 
dephosphorylation by insulin, Slingshot1 (SSH1) was identified as the cofilin 
phosphatase in the L6 muscle cells.  SSH1 activity was shown to predominate 
over that of LIMK in these muscle cells, with LIMK knockdown having little impact 
upon cofilin phosphorylation status.  Our data support this and further show that 
while PAK1 is upstream of cofilin, IPA3-mediated inhibition of PAK1 fails to inhibit 
LIMK activation.  Alternative to activation by PAK1, LIMK may become activated 
in response to insulin stimulation via Rho kinase or ‘ROCK’ activation [202]. 
Regardless though, this LIMK pathway is expected to be a lesser contributor to 
actin remodeling given the substantial impact of IPA3-mediated PAK1 inhibition. 
An additional open question is whether SSH1 activity is regulated by PAK1, 
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either directly or indirectly. SSH1 is activated upon its dephosphorylation, in 
response to calcineurin as well as to formation of polymerized actin; SSH1 
contains an actin binding domain. SSH1 is inactivated by protein kinase D1, 
phosphorylating a serine residue located in its actin-binding motif. The PAK4 
isoform, a Group II PAK, is known to negatively regulate SSH1 activity, although 
this is the opposite of what one would expect given that in skeletal muscle cells, 
cofilin is dephosphorylated in response to insulin and in a pPAK1-dependent 
manner. Hence, our data would appear to be consistent with PAK1 acting 
upstream as an indirect regulator of SSH1, via its ability to induce actin 
polymerization. 
In L6 skeletal muscle cells, cofilin dephosphorylation requires a prior 
accumulation of polymerized actin driven by Arp2/3.  The Arp2/3 complex, an 
actin-nucleating complex in association with cofilin, is implicated in the regulation 
of cortical actin remodeling in skeletal muscle cells. In other cell types PAK1 is 
known to regulate actin remodeling by phosphorylating p41-ARC, a regulatory 
subunit of Arp2/3 complex [122]. Additionally, the Arp2/3 complex with its 
activator N-WASP is involved in the recycling of GLUT4 transporters via 
regulating cortical actin remodeling in adipocytes. Studies are underway to 
investigate the role and placement of p41-ARC and N-WASP in the PAK1-
dependent insulin signaling pathway in skeletal muscle cells.  Additionally, PAK1 
signaling to other downstream factors such as cortactin, Myo1c and Filamin A 
should be investigated, since these targets are known to bind to PAK1 in non-  
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Figure 2.6. Proposed model for insulin-stimulated PAK1 signaling in 
skeletal muscle.  Insulin-stimulated PAK1 activation initiates F-actin remodeling 
by regulating the activity of cofilin and is required for mobilization of GLUT4 
vesicles to the cell surface, resulting in glucose uptake. 
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muscle cells and have been implicated as indirect effectors of glucose uptake 
[203]. In L6-GLUT4-myc myotubes the depletion of Rac1 results in the ablation of 
PAK1 activation, as does the treatment of mouse skeletal muscle with the Rac1 
inhibitor NSC23766. Moreover, skeletal muscle-specific Rac1 KO mice have 
impaired skeletal muscle PAK1 signaling, suggesting that PAK1 is downstream 
of Rac1. However, PAK1 has also been implied to function upstream of Rac1 in 
other cell types, by phosphorylating RhoGDI to yield activated Rac1 [204].  
Hence, future studies are required to investigate the potential additional 
placement of PAK1 upstream of Rac1 using PAK1 inhibitors and skeletal muscle-
specific PAK1 KO mice.  
The fact that IPA3 action on GLUT4 translocation and cofilin phosphorylation 
status is reminiscent to that of PAK1 depletion in vivo suggests that its actions on 
muscle cells are unlikely to arise from effects on targets other than PAK1. 
However, we cannot discount that the inhibitory action on actin remodeling is 
entirely due to its action on PAK1.  
In summary, we have demonstrated that PAK1 signals to cofilin in response to 
insulin and facilitates the cortical actin remodeling in skeletal muscle cells. With 
this, PAK1 mediates the GLUT4 vesicle translocation to the cell surface and 
results in glucose uptake into the skeletal muscle cells.  Interestingly, a GWAS 
study has localized PAK1 to the T2D susceptibility locus on human Chromosome 
11 [205, 206], and PAK1 deficiency is linked to glucose intolerance, insulin 
resistance and T2D in human and rodent models of these pathophysiological 
states [207]. Altogether, these data suggest that a decrease in PAK1 
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abundance/function might be a potential risk factor for pre-diabetes susceptibility.  
Hence strategies/methods to restore the function or abundance of PAK1 in 
skeletal muscle could be useful for re-establishing insulin action and euglycemia.  
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CHAPTER 3 
PAK1 SIGNALS TO p41-ARC AND N-WASP IN RESPONSE TO INSULIN TO 
EVOKE ACTIN REMODELING AND GLUCOSE UPTAKE IN SKELETAL 
MUSCLE CELLS 
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3.1. SYNOPSIS 
Defects in GLUT4 translocation are associated with peripheral insulin resistance, 
pre-clinical diabetes and eventual progression to T2D. Recruitment of GLUT4 to 
the PM of skeletal muscle cells requires filamentous (F)-actin remodeling. 
Although in vitro data implicates the neural Wiskott-Aldrich syndrome protein (N-
WASP) in insulin-dependent cortical F-actin rearrangement, the mechanism of 
action involving N-WASP, and any relatedness to skeletal muscle function, 
remains elusive. Here we show that inactivation of N-WASP by its specific 
inhibitor, Wiskostatin, fully abrogates the insulin-stimulated increase in GLUT4 
translocation to the plasma membrane in skeletal muscle cells. Toward 
interrogating the underlying mechanism, interactions between N-WASP and actin 
as well as actin binding proteins Cortactin and ARP2/3 complex were assessed, 
given that the latter proteins are implicated in actin remodeling in clonal muscle 
cells. Indeed, a ~1.5 fold increased binding of Cortactin to N-WASP with insulin 
stimulation was detected using mouse skeletal muscle lysates. Moreover, 
interaction of N-WASP with both actin and p41-ARC (a regulatory subunit of the 
ARP2/3 complex) also increased upon insulin stimulation, and this interaction 
was abrogated upon inhibition of PAK activation by IPA3 (an inhibitor of PAK 
activation) in skeletal muscle cells. In sum, these results suggest that N-WASP 
facilitates Cortactin- and p41-ARC-mediated F-actin remodeling for insulin-
stimulated GLUT4 vesicle translocation to the PM of skeletal muscle cells.  
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3.2. INTRODUCTION 
 
Insulin stimulates glucose uptake into skeletal muscle and adipose tissue by 
mobilizing intracellular vesicles containing the glucose transporter GLUT4 to the 
PM [179],[180]. Integration of GLUT4 into the PM facilitates glucose entry into the 
cell. Skeletal muscle accounts for ~80% of insulin-dependent postprandial 
glucose uptake [208]; defective glucose clearance results in insulin resistance 
and contributes to the development of T2D. Hence, targeting mechanisms to 
promote insulin-stimulated GLUT4 vesicle mobilization provides a means to 
restore insulin sensitivity.  
Skeletal muscle cells respond to insulin via the presence of insulin receptors at 
the cell surface, triggering the canonical insulin signaling pathway: insulin binds 
to the insulin receptor to induce autophosphorylation, which in turn induces the 
tyrosine phosphorylation of insulin receptor substrate (IRS), then PI3K. In 
skeletal muscle, the pathway downstream of PI3K bifurcates into two parallel and 
independent arms: one arm leads to phosphorylation of AKT, and the second 
arm leads to the activation of the monomeric small GTPase protein Rac1 [95]. 
Rac1 activation evokes the phosphorylation of its effector protein, PAK1. While 
the events downstream of the AKT arm of insulin-signaling are well-documented 
in these glucose uptake mechanisms, the Rac1-PAK1 aspect remains 
undetermined.  
In humans, insulin-induced PAK1 activation is impaired in skeletal muscle in 
acute (intralipid infusion) and chronic (high fat diet-induced obesity and T2D) 
insulin resistant states, implicating the requirement of PAK1 for insulin-dependent 
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glucose uptake/disposal [176]. Studies using whole-body PAK1 knockout mice 
replicate these findings, as did use of the Group 1 PAK1 inhibitor IPA3, providing 
evidence for PAK1 involvement in actin remodeling to promote GLUT4 vesicle 
translocation [209]. Stimulus-induced actin cytoskeletal remodeling requires the 
action of multiple actin binding proteins that control the spatial and temporal 
polymerization and depolymerization events. In a non-canonical signaling 
mechanism, PAK1 was found to regulate insulin-induced actin remodeling in 
skeletal muscle cells in a LIM Kinase independent manner, signaling to cofilin 
(actin severing protein) to initiate actin depolymerization. However, the mode by 
which PAK1 regulates actin polymerization has yet to be established. 
Studies of actin remodeling in skeletal muscle cells have revealed Cortactin to be 
required for insulin-induced GLUT4 translocation and glucose uptake 
[123]( Nazari H etal 2011). Cortactin is an actin nucleation-promoting factor that 
mediates the assembly and organization of actin cytoskeletal meshwork [210], 
and has been shown in other cell types to be phosphorylated by PAK1. In Hep2b 
clonal hepatocytes, the phosphorylation of Cortactin by PAK1 specifically at 
Ser405 and Ser418 increased the affinity of Cortactin for a known enhancer of 
actin polymerization, neuronal Wiskott-Aldrich syndrome protein (N-WASP) [124]. 
However, N-WASP has not been investigated in the process of insulin-induced 
actin remodeling or glucose uptake in skeletal muscle cells. Moreover, again in 
other cell types, PAK1 is known to regulate actin remodeling by phosphorylating 
p41-ARC, a regulatory subunit of the ARP2/3 complex[122]. Although ARP2/3 
has been implicated as a positive factor in GLUT4 translocation in skeletal 
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muscle cells, involvement of p41-ARC remains untested. Hence, PAK1 may 
signal through p41-ARC-ARP2/3 or cortactin-N-WASP, or both pathways, to 
evoke actin remodeling and glucose uptake via GLUT4 vesicle mobilization in 
skeletal muscle cells.  
Towards testing these possible pathways, we used chemical inhibitors, live cell 
imaging and immunoprecipitation studies to discern the insulin-induced changes 
in protein-protein complexes concurrent with changes in glucose uptake and 
GLUT4 translocation. N-WASP was determined to be essential as a downstream 
mediator of PAK1 in insulin-induced actin remodeling, GLUT4 translocation, and 
associated with Cortactin. Further, PAK1 activation was required for its 
association with p41-ARC and actin in skeletal muscle cells. Altogether, these 
findings elucidate new elements of the insulin signaling pathway downstream of 
Rac1-PAK1 in skeletal muscle that dictate the cortical F-actin remodeling and 
subsequent mobilization of GLUT4 vesicles and fusion to the cell surface.  
3.3. MATERIALS AND METHODS 
3.3.1. Materials 
Rat L6 GLUT4-myc skeletal muscle cells expressing c-myc tagged GLUT4 
protein were purchased from Kerafast and developed as described [211]. MEMα 
medium was purchased from Invitrogen (Carlsbad, CA). Porcine insulin, DMSO, 
wiskostatin (WISK) and rabbit anti-Actin antibody were purchased from Sigma 
(St.Louis, MO). EnzyFluo glucose uptake assay kit was obtained from BioAssay 
systems (Hayward, CA). The LifeAct-GFP plasmid was kindly provided by Dr. 
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Louis Philipson (University of Chicago, IL [191]). The F-G actin Ratio kit was 
obtained from Cytoskeleton (Denver, CO). IPA3, protein G+ beads and anti c-
myc antibody were purchased from Santa Cruz Biotech (Santa Cruz, CA). 
Phospho-PAK1T423/phospho-PAK2T402, PAK1, N-WASP, Cortactin and antibodies 
were obtained from Cell Signaling (Danvers, MA). p41-ARC antibody was from 
Abcam (Company). Fetal bovine serum and goat anti-mouse horseradish 
peroxidase secondary antibody were obtained from Thermo-Fisher Scientific 
(Rockford, IL). Goat anti-rabbit horseradish peroxidase secondary antibody was 
purchased from Bio-Rad (Hercules, CA). Enhanced chemiluminescence reagent 
(ECL), ECL prime and SuperSignal™ Femto were purchased from GE 
Healthcare (Piscataway, NJ) and Pierce (Rockford, IL), respectively.  
3.3.2. Cell culture  
L6-GLUT4myc myoblasts were grown as monolayers in MEM-α  medium 
supplemented with 10% fetal bovine serum and 1% (v/v) antibiotic-antimycotic 
solution. L6-GLUT4-myc myoblasts at 40% confluency were differentiated into 
myotubes by incubation in MEM-α medium containing 2% fetal bovine serum 
[212, 213]. For all the studies involving IPA3, L6-GLUT4-myc myoblasts (~ 90% 
confluency) were pre-incubated in serum-free medium for 2 hr with IPA3 added 
for the times indicated in the figures just prior to insulin stimulation (100 nM). 
Similarly, all the experiments using WISK were pre-incubated in serum-free 
medium for 2 hr, with WISK and insulin (100 nM) added simultaneously. Cells 
were harvested in 1% NP-40 lysis buffer containing 25 mM HEPES, pH 7.4, 1% 
Nonidet P-40, 10% glycerol, 50 mM sodium fluoride, 10 mM sodium 
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pyrophosphate, 137 mM NaCl, 1 mM sodium vanadate, 1 mM 
phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 1 µg/ml pepstatin, 5 µg/ml 
leupeptin and cleared of insoluble material by centrifugation at 13,000 x g for 10 
min at 40C. The cleared lysate was used for immunoblot analyses.  
 3.3.3. Cell surface GLUT4myc detection 
Cell surface GLUT4myc detection was performed as described [194].  Briefly, L6-
GLUT4-myc myoblasts were incubated in serum-free medium containing WISK 
(10 µM) or vehicle (DMSO) for 20 min together with insulin (100 nM) at 37oC.  
Cells were then fixed with 4% paraformaldehyde in PBS for 20 min at room 
temperature (RT), blocked in Odyssey Blocking Buffer (LI-COR Biosciences, 
Lincoln, NE) for 1 h at RT and incubated with mouse anti-Myc antibody (1:100) 
overnight at 4oC. Cells were extensively washed with PBS and then incubated 
with infrared (IR)-conjugated secondary antibody for 1 h at RT. 
Immunofluorescence intensity of the IR-conjugated secondary antibody was 
quantified using the LiCor Odyssey CLx infrared imaging system (LI-COR 
Biosciences, Lincoln, NE) and data normalized to SYTO 60 (Invitrogen, Carlsbad, 
CA), a red fluorescent nucleic acid stain.  
3.3.4. Immunoblotting 
Proteins in cell lysates were resolved using 10% SDS-PAGE and transferred to 
PVDF or Nitrocellulose membranes for immunoblotting. Immunoreactive bands 
were visualized using Enhanced Chemiluminescence (ECL) or ECL Prime 
reagents and imaged using a Chemi-Doc Touch gel documentation system (Bio-
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Rad). N-WASP and Cortactin proteins were visualized using goat anti-rabbit 680 
secondary antibody (1:10000) for detection using Odyssey-CLx LI-COR.  
3.3.5. Live-cell imaging 
L6-GLUT4myc myoblasts were seeded on MatTek glass bottom culture dishes at 
a density of 300,000 cells per 35 mm dish. At ~40% confluency, cells were 
transfected with the LifeAct-GFP plasmid using Effectene transfection reagent 
(Qiagen, Valencia, CA). Live-cell imaging was performed on cells 48 hr post-
transfection. Briefly, on the day of the experiment the cells were pre-incubated in 
serum-free KRPH buffer (120 mM NaCl, 2.5 mM KCl, 20 mM HEPES, 1.2 mM 
MgSO4, 1 mM NaH2PO4, and 2 mM CaCl2) supplemented with 5 mM D-glucose 
for 3 h, then DMSO or WISK was added 10 min before the addition of 100 nM 
insulin for live-cell imaging. LifeAct-GFP imaging was performed on a Zeiss Axio 
Observer with a Plan-Apochromat 63x objective and sample chamber with 
temperature, humidity and CO2. Images were captured every 60 sec starting 1 
min before the addition of insulin and continued through until 12 min after the 
addition of insulin.  
3.3.6. Immunoprecipitation 
L6-GLUT4myc myoblasts were incubated in serum-free medium for 2 hr, pre-
treated with IPA3 for 50 min and stimulated with 100 nM insulin for 20 min. 
Initially, 2.5 mg of whole cell lysate was pre-cleared by incubating with 0.5 µg of 
c-myc antibody and 20 µl of Protein G Agarose beads for 30 min. Proteins were 
immunoprecipitated by incubating the pre-cleared lysate with 3.75 µg of N-WASP 
antibody overnight, followed by incubation with 80 µl of Protein-G Agarose beads 
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for 2 hr. Immunoprecipitated proteins were washed three times with lysis buffer 
and eluted with SDS sampling buffer containing DTT. Eluted proteins were 
resolved using 10% SDS-PAGE and transferred to PVDF or nitrocellulose 
membranes for immunoblotting. Ponceau S staining was used to evaluate protein 
loading. Since N-WASP antibodies failed for immunoblot detection of N-WASP 
immunoprecipitated, possibly due to steric hindrance of the epitope, cells were 
also transfected with recombinant GFP-tagged N-WASP and anti-GFP co-
immunoprecipitations performed.  
3.3.7. Statistical analysis 
All data were expressed as the average ± SE using Students t-test. Time course 
and dose response data were evaluated with one-way ANOVA and a Tukey post-
hoc test using GraphPad PrismTM (La Jolla, CA). 
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3.4. RESULTS 
 
3.4.1. N-WASP is required for insulin-stimulated GLUT4 vesicle 
translocation to support glucose uptake. 
To determine the role of N-WASP in insulin-dependent GLUT4 translocation and 
glucose uptake in skeletal muscle cells, WISK, a specific inhibitor of N-WASP 
was used. WISK is an allosteric inhibitor of N-WASP that interacts with a cleft in 
the regulatory GTPase binding domain of N-WASP and stabilizes the native 
auto-inhibited conformation. Multiple dosages of WISK were tested in myoblasts 
to determine if any effects upon insulin-induced GLUT4 translocation to the PM 
were apparent. Insulin induced the mobilization of GLUT4 from the intracellular 
compartments to the plasma membrane of L6-GLUT4myc myoblasts, and as little 
as 10 µM WISK attenuated insulin-stimulated GLUT4 mobilization by 80% (Fig. 
3-1a-b). Higher concentrations of WISK exhibited aberrant effects on basal 
GLUT4 transport to the PM. Therefore, WISK was used at 10 µM for 20 min in 
subsequent experiments.  
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Figure 3.1. Inhibition of N-WASP blunts insulin-dependent GLUT4 
translocation in L6 GLUT4myc myoblasts. A) L6-GLUT4myc myoblasts were 
treated with DMSO- or 10 µM Wiskostatin(WISK) and stimulated with 100 nM 
insulin for 20 min simultaneously. Cells were fixed and left unpermeabilized for 
labeling with anti-myc antibody. Immunofluorescent intensity of cell surface 
GLUT4 was normalized to the nucleic acid staining dye, Syto 60. Values are 
means ± SEM. N=3, *p<0.05 B) L6-GLUT4myc myoblasts were treated with 0, 5, 
10, 20, and 25uM  Wiskostatin  together with 100 nM Insulin for a total of 20 mins. 
Cells were fixed and left unpermeabilized for labeling with anti-myc antibody. 
Immunofluorescent intensity of cell surface GLUT4 was normalized to the nucleic 
acid staining dye, Syto 60. Values are means ± SEM. N=3, *p<0.05  
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3.4.2. N-WASP regulates insulin-induced localized F-actin remodeling 
in L6-GLUT4myc myoblasts. 
To determine the requirement for N-WASP signaling in the process of F-actin 
remodeling in skeletal muscle cells, live-cell imaging of L6 myoblasts harboring 
the Lifeact-GFP biosensor was performed, as described previously [209]. LifeAct 
is a 17 residue peptide from the actin binding protein Abp140 linked to the N-
terminus of GFP to form LifeAct-GFP, binding specifically to F-actin in live cells 
without adversely affecting F-actin dynamics. Insulin-stimulated changes in actin 
polymerization in single cells of L6 myoblasts were captured over a period of 10 
min, showing actin remodeling within 5-6 min of insulin addition (Fig. 3-2a). The 
addition of 10 µM WISK at the time of insulin addition fully ablated any actin 
remodeling. 
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Figure 3.2. Insulin-stimulated F-actin remodeling requires N-WASP 
activation. A) L6-GLUT4myc myoblasts were transfected with Lifeact-GFP. After 
48 h, cells were pretreated with vehicle (DMSO) or 10 µM Wiskostatin for 10 min 
and live cell confocal imaging was initiated. F-actin remodeling was monitored 
every minute from 1 min prior to insulin addition to 10 min after insulin addition. 
Arrows indicate sites of F-actin remodeling. At least 20 GFP-positive cells were 
live-imaged, with >10 treated with WISK, from 3 independent passages of L6 
cells. B) Filamentous (F) and Globular (G) actin from L6-GLUT4myc myoblasts 
treated with vehicle (DMSO) or 10 µM WISK, left unstimulated (Basal) or 
stimulated with 100 nM insulin for 20 min, were resolved on SDS-PAGE for 
immunoblotting using anti-actin. A representative blot showing F/G-actin ratio is 
calculated as a percent of total per sample. C) Quantitative bar graph 
representation of F/G actin ratio from three independent passages of L6 cells; 
p>0.05 for all comparisons. 
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WISK did not alter global actin cytoskeletal changes, since the F/G-actin ratio 
remained similar, as compared with vehicle-treated cells (Fig. 3-2b-c). 
Interestingly, insulin did not evoke global changes to F/G-actin ratios either, 
supporting the prevailing concept in the field that insulin induces localized actin 
remodeling. These data suggest that N-WASP is required for insulin stimulated 
actin remodeling to support GLUT4 vesicle translocation in skeletal muscle cells. 
 3.4.3. N-WASP requires PAK1 activity for its interaction with actin and 
Cortactin in response to insulin. 
Although PAK1 is known to regulate insulin-induced GLUT4 translocation via F-
actin remodeling in skeletal muscle cells, the downstream signaling pathway 
involving PAK1 remains unexplored. Previously, we have shown that PAK1 
indirectly regulates Cofilin activity to induce actin depolymerization, which is one 
of the two arms of actin remodeling. Here, we explored the downstream signaling 
cascade of PAK1 that regulates actin polymerization, the other arm of actin 
remodeling. Immunoprecipitation studies with N-WASP revealed a 6-fold 
increase in association of actin with N-WASP in response to insulin stimulation 
(Fig. 3-3a), and this interaction was significantly reduced by ~67% in cells treated 
with the PAK inhibitor, IPA3. The actions of insulin and IPA3 were validated in 
each independent experiment using a phospho-specific PAK antibody (Fig. 3-3b), 
Similar to WISK inhibition, inhibition  		3 
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Figure 3.3. Inhibition of PAK1 activation decreases the insulin-stimulated 
association of Actin with N-WASP in L6 GLUT4myc myoblasts. A) L6-
GLUT4myc myoblasts were pre-treated with DMSO- or 25 µM IPA3 for 50 min 
and stimulated with 100 nM insulin for additional 10 min. Whole cell lysates were 
subjected to immunoprecipitation with anti-N-WASP antibody and precipitated 
proteins were resolved using SDS-PAGE for immunoblot analyses. Actin levels 
were normalized for loading using ponceau S staining of the same blot, in three 
independent sets of cell lysates. Values represent the means ± SEM; *p<0.05, vs. 
insulin-stimulated vehicle control. B) L6-GLUT4myc myoblasts pretreated with 
vehicle (DMSO) or 25 µM IPA3 were stimulated with 100nM insulin for 10 min. F 
and G-actin were separated by ultracentrifugation and analyzed on SDS-PAGE. 
C) Whole cell lysates from the above were analyzed for p-PAK1/2T423/T402C and 
total PAK1 protein levels. D) IP of EGFP-N-WASP protein from L6-GLUT4myc 
myoblasts overexpressing EGFP-NWASP protein was performed as mentioned 
in (A) and Actin levels were normalized for loading to GFP. Bars represent the 
means ± SEM in 3 independent sets of L6 cells; p>0.05. 
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of PAK activation had no global effects on the F/G actin ratio (Fig. 3-3c). These 
data support the concept of insulin-stimulated PAK1 activation fostering the 
association of N-WASP with the actin cytoskeleton to evoke localized actin 
remodeling in skeletal muscle cells. 
Cortactin is a known regulator of actin polymerization and its phosphorylation by 
PAK1 on Ser405 and Ser418 has been shown to increase its interaction with N-
WASP in different cell types [124]. To interrogate the role of PAK1 in the 
interaction of N-WASP and Cortactin, hindlimb muscle homogenates prepared 
from wild-type C57B/L6J (WT) and whole body PAK1-/- homozygous knockout 
(KO) mice injected with insulin or saline were subjected to immunoprecipitation 
with anti-N-WASP antibody. Strikingly, immunoprecipitation of N-WASP resulted 
in a 2.6-fold increased co-precipitation of Cortactin from insulin-stimulated WT 
muscle homogenates, as compared with saline-injected homogenates (Fig. 3-4). 
The N-WASP association with cortactin was virtually undetectable in the skeletal 
muscle of PAK1-/- KO mice, under either basal or insulin-stimulated conditions. 
Notably, cortactin in primary mouse skeletal muscle was >90 kDa in molecular 
weight, higher than that in L6 cells (~75-80 kDa). Blocking peptide studies show 
this band to be bona fide Cortactin; mass spectrometry studies are underway to 
confirm this unusual finding. 
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Figure 3.4. PAK1 regulates insulin-dependent N-WASP-Cortactin 
interaction in primary skeletal muscle tissue. Hindlimb muscle of saline/ 
insulin stimulated WT and global PAK1 KO-/- mice was homogenized and 4 mg 
protein of tissue homogenate was used in immunoprecipitation reactions 
containing anti-N-WASP antibody. Precipitated proteins were resolved on SDS-
PAGE for immunoblot (IB) analysis using antibodies detecting cortactin and N-
WASP. The cortactin/N-WASP ratio is derived from one full set of mouse 
hindlimb homogenates. 
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3.4.4. PAK1 activation is required for the interaction with N-WASP in 
insulin-stimulated L6-GLUT4myc myoblasts. 
N-WASP and Cortactin are actin nucleation promoting factors that regulate actin 
polymerization through the actin branching complex, ARP2/3. PAK1 has been 
shown to regulate this protein complex by phosphorylating p41-ARC, a regulatory 
subunit of ARP2/3 complex, in a breast cancer cell line. Immunoprecipitation 
studies revealed the interaction of p41-ARC with N-WASP in L6-GLUT4myc 
myoblast lysates, and the abundance of these complexes increased in response 
to insulin-stimulation (Fig. 3-5a). This insulin-stimulated N-WASP-p41-ARC 
association was ablated by pre-treatment of myoblasts with the PAK inhibitor 
IPA3. These findings suggested that in skeletal muscle cells, PAK1 might signal 
downstream to p41-ARC to foster the associations of N-WASP-cortactin in an 
insulin-dependent manner.  
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Figure 3.5. Insulin-dependent interaction of p41-ARC with actin is regulated 
by PAK1 in L6-GLUT4myc myoblasts. L6-GLUT4myc myoblasts were pre-
treated with DMSO- or 25 µM IPA3 for 50 min and stimulated with 100 nM insulin 
for additional 10 min. Whole cell lysate were immunoprecipitated with N-WASP 
antibody and interacting partners were determined by western blotting analysis. 
Ratio of p41-ARC/Ponceau S staining of the same blot is listed below the 
ponceau S. Values are means ± SEM. N=3, *p<0.05.  
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3.5. DISCUSSION 
In the current study, we report the existence of a new signaling pathway 
downstream of PAK1 that regulates cortical F-actin polymerization in skeletal 
muscle tissue and cells. As depicted in the model derived from our new and 
previously published findings (Fig. 3-6), insulin stimulation induces Rac1 
activation, giving rise to PAK1 phosphorylation and p41-ARC association with N-
WASP, which promotes N-WASP binding to Cortactin and F-actin polymerization. 
These insulin-responsive interactions were ablated by exposure of cells to 
pharmacological inhibitors of PAK1 phosphorylation (IPA3), placing them 
downstream and dependent upon PAK1 activation. Supportive of the 
pharmacological data, skeletal muscle from PAK1 knockout mice also lacked 
these interactions. PAK1 activation may foster p41-ARC-N-WASP interaction via 
its reported ability to directly serve as kinase to phosphorylate p41-ARC; mass 
spectrometry studies are currently underway to test this feature. Live-cell imaging 
showed that WISK signaling to support F-actin polymerization in muscle cells 
facilitated localized and not global action polymerization, consistent with the 
concept of actin remodeling, and was required for insulin-stimulated GLUT4 
translocation and fusion with the plasma membrane.  
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Figure 3.6. Insulin binds to insulin receptor (IR) and results in the activation 
of Rac1 in an phosphatidylinositol-3-kinase (PI3K) dependent manner. 
Activated Rac1 likely recruits its downstream effector PAK1 and initiates the 
dynamic cortical F-actin remodeling which is regulated by actin binding proteins, 
Cofilin, N-WASP, Cortactin and ARP2/3 complex. The cortical F-actin remodeling 
facilitates the movement of GLUT4 storage vesicles (GSV) to the cell surface and 
results in glucose uptake. 
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Finding p41-ARC to serve as a downstream effector of PAK1 signaling in the 
insulin-induced pathway towards actin remodeling represents the first implication 
of this factor in the process of insulin-stimulated GLUT4-mediated glucose 
uptake. PAK1 phosphorylates p41-ARCT21 in MCF-7 cells upon epidermal growth 
factor (EGF) stimulation [122]. p41-ARC is one of two principle ARP2/3 subunits 
used somewhat interchangeably amongst cell types, with the other being 
ARPC1A. Interestingly, recent studies by Abella et al in both in vitro as well as in 
vivo (in HeLa cells) demonstrated that cortactin binds and stabilizes ARPC1B/ 
ARPC5L containing complex to promote actin assembly and assist in the 
formation of long actin tails compared to the short actin tails formed by the p41-
ARC/ARPC5 containing ARP2/3 complexes. However, our findings here along 
with others [214] show p41-ARC to be the more likely participant in skeletal 
muscle. Although ubiquitously expressed, p41-ARC is less-often reported as 
participating in these ARP2/3 complexes. 
PAK1 signaling through p41-ARC to N-WASP also provides a novel aspect to the 
canonical insulin signaling cascade in skeletal muscle cells. N-WASP was shown 
to be important for GLUT4 translocation in 3T3L1 adipocytes [215], but signaling 
to evoke actin remodeling is distinct from that in skeletal muscle cells, reportedly 
involving the small GTPase TC10, and independent of Rac1 or PI3K [215-217] . 
As in our skeletal muscle cells, N-WASP was implicated in actin remodeling in 
adipocytes, although use of transient over-expression of a dominant negative N-
WASP mutant precludes the ability to conclude that N-WASP activation per se is 
responsible. Herein, we used WISK-mediated inhibition of N-WASP activation, 
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and this rapidly and thoroughly abolished insulin-induced cortical actin 
remodeling and decreased insulin-stimulated GLUT4 translocation in skeletal 
muscle cells. WISK inhibited these events during the insulin-stimulation period – 
no lengthy pre-treatment was required to halt these signaling events. This 
supports the concept that N-WASP activation, and not its synthesis or the 
synthesis of other proteins, underlies the PAK1-mediated cascade requiring N-
WASP. Furthermore, that insulin-stimulated AKT phosphorylation remained 
unchanged in the presence of WISK, implicates N-WASP in a parallel pathway, 
leading to GLUT4 vesicle mobilization in skeletal muscle. An alternative to this 
would be that N-WASP acts downstream of AKT; this has not been demonstrated 
to date in any cell type to the best of our knowledge. This is consistent with data 
using inhibitors of PAK1 and Rac1, and the notion that a Rac1→PAK1→p41-
ARC→N-WASP signaling pathway occurs independent of the established AKT 
signaling pathway in skeletal muscle cells.  
In another new step in this cascade, insulin stimulation increased the association 
of N-WASP with Cortactin in mouse skeletal hindlimb muscle homogenates, and 
this was completely abolished in the skeletal muscle of global PAK1 KO-/- mice, 
indicating a role for PAK1 in regulating this interaction; this was fully supported in 
L6-GLUT4myc myoblasts. In non-muscle cell types, PAK1 has been shown to 
phosphorylate Cortactin at Thr21, and this phosphorylation is critical for the 
increased association of N-WASP with Cortactin to promote actin polymerization 
under stimulated conditions in Hep2b cells [124]. While the precise mechanism 
underlying insulin-stimulated N-WASP activation remains to be elucidated, 
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reports from other cell types suggest testable options. For example, N-WASP 
harbors an Cdc42/Rac interactive binding domain (CRIB), such that Rac1 could 
directly regulate N-WASP, over-stepping the need for PAK1 [218]. However, our 
data using IPA3 indicate a requirement for PAK1 in activating N-WASP in 
skeletal muscle cells. Alternatively, PAK1 and Rac1 could dually regulate the 
activation of Cortactin and N-WASP, respectively. Since Cortactin and N-WASP 
are known to synergistically activate ARP2/3 complex, via Cortactin binding to 
ARP3, and N-WASP binding to p41-ARC and ARP2 [219] this dual regulation 
hypothesis will need to be carefully examined.  
This is the first identification of the polymerization arm of the actin remodeling 
cycle in skeletal muscle, involving p41-ARC-N-WASP--Cortactin interactions. 
However, this signaling cascade, overseeing the process of F-actin 
polymerization, must be managed with respect to the actin depolymerization 
signaling cascade, involving actin severing proteins such as Cofilin and SSH1, as 
these are also insulin regulated [121]. Indeed, the product of depolymerization is 
G actin monomers, and these monomers are the building blocks of F-actin 
filaments. Conceptually, it is by the compilation of these opposing arms of the 
actin remodeling cycle that the spatial and temporal rearrangement of cortical F-
actin that creates tracks for the GLUT4 vesicles to move along to the PM. Future 
studies are warranted to discern the detailed mechanisms regarding insulin’s 
ability to orchestrate the balance favoring actin polymerization, and actin 
depolymerization.  
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Altogether, our new findings place PAK1 as a central regulator of insulin 
sensitivity to maintain glucose homeostasis, and a reduction in PAK1 signaling/ 
abundance might be a potential risk factor for pre-diabetes susceptibility. 
Because PAK1 is such a central ‘hub’ for activities in actin remodeling in many 
cell types, identification of the primary pathways emanating from PAK1 in skeletal 
muscle will be important as a means to intervene beyond any PAK1 mutations or 
deficiencies. This will also circumvent any issues raised by retrospective samples 
associating PAK1 hyperactivation with various types of cancer [220]. Hence, 
efforts to restore PAK1 signaling leading to GLUT4 vesicle exocytosis in skeletal 
muscle carries potential to reinstate insulin sensitivity in pre-diabetic and Type 2 
diabetic individuals. 
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CHAPTER 4 
DISCUSSION 
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4.1. OVERVIEW 
The objective of my dissertation was to determine the placement and function of 
PAK1 and its downstream signaling pathway(s) required for the maintenance of 
skeletal muscle insulin sensitivity. Toward this, the requirement of PAK1 
signaling function in skeletal muscle glucose uptake was examined followed by 
determining the downstream signaling targets of PAK1 in regulating the cortical 
F-actin remodeling process, which is a pre-requisite for GLUT4 vesicle 
mobilization in skeletal muscle. Here, I will discuss findings from each chapter, 
alternative strategies and future studies required to further our understanding on 
the GLUT4 vesicle exocytosis process in skeletal muscle. Finally, the overall 
impact of the current findings in the control of whole body glucose homeostasis 
and strategies to prevent/ treat insulin resistance or T2D will be discussed. 
4.1.1. Five major findings regarding PAK1 in skeletal muscle insulin 
sensitivity 
PAK1 is the best-characterized member of the group I PAKs and is a widely-
known regulator of cytoskeletal remodeling, cell survival, motility and proliferation. 
Previously, studies from our laboratory and others using whole body PAK1 KO 
mice revealed PAK1 to be a key critical required signaling protein in the process 
of insulin-stimulated GLUT4 translocation to the skeletal muscle cell surface. My 
studies corroborate these findings, and more importantly, further detail the 
function(s) of PAK1 in signaling downstream to previously unknown targets in 
skeletal muscle cells that lead to F-actin remodeling, eliciting glucose uptake into 
skeletal muscle. In addition to elucidating the signaling pathway emanating 
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immediately downstream of PI3K→Rac1 in skeletal muscle cells, five major 
discoveries from the current studies were made: 1) that PAK1 is activated by 
Rac1 in muscle cells, and its function is required for insulin-induced GLUT4 
storage vesicle exocytosis and subsequent glucose uptake into skeletal muscle 
cells; 2) that PAK1 activation is required for the insulin-stimulated cortical actin 
remodeling in L6-GLUT4myc cells; 3) that PAK1 signals via a non-canonical 
LIMK-independent route to cofilin to regulate insulin-dependent F-actin 
remodeling in skeletal muscle cells; 4) that PAK1 regulates an atypical complex 
of actin-modifying proteins in skeletal muscle cells in response to insulin 
stimulation, including N-WASP, Cortactin and p41-ARC; and 5) that N-WASP 
functions in a PAK1-dependent manner to trigger insulin-stimulated F-actin 
remodeling in skeletal muscle cells.  
4.1.2. PAK1 is involved upstream at the early step of initiating actin 
remodeling and triggering F-actin polymerization, in addition 
to depolymerization 
My data established that although both PAK1 and PAK2 are present in L6-
GLUT4myc myoblasts and skeletal muscle tissue, only PAK1 was implicated in 
insulin-induced GLUT4 mobilization to the cell surface. PAK2 knockdown was 
without effect upon insulin-stimulated GLUT4 translocation in skeletal muscle 
cells, and PAK3 was below the limit of detection both at mRNA as well as protein 
level in L6-GLUT4myc myoblasts and mature skeletal muscle tissue. Prior to my 
investigations PAK1 had been implicated in cofilin activation, and cofilin is 
involved in the depolymerization of F-actin. My research however showed that 
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PAK1 was actually involved upstream of this event, at the early step of initiating 
actin remodeling and triggering F-actin polymerization, via ARPC1, Cortactin and 
N-WASP complex assembly. In this manner, PAK1 initiates the start of the cycle 
of F-actin remodeling, first polymerizing F-actin into tracks, and then recycling via 
cofilin actions of depolymerization. Regarding cofilin regulation, in neuronal cells 
PAK1 was shown to activate its substrate LIMK, with LIMK then triggering cofilin 
phosphorylation [221]. Testing this in skeletal muscle cells, my research revealed 
that upon insulin stimulation PAK1 signals to activate cofilin (dephosphorylation) 
in an LIMK-independent pathway, suggesting the existence of an alternate 
pathway that leads to the dephosphorylation of cofilin. To date, there are only two 
known cofilin phosphatases, SSH and Chronophin proteins. Studies by Kligys et 
al revealed that Rac1 mediates the activation of cofilin by regulating SSH in 
keratinocytes via the action of 14-3-3, a phospho-serine/threonine binding protein 
[222]. With PAK1 being a serine/threonine kinase that has been previously 
shown to regulate the 14-3-3 binding to a GEF in non-muscle cell types [223], it 
is conceivable that PAK1 may activate SSH activity indirectly via the 14-3-3 
protein to activate cofilin (dephosphorylation) in response to insulin in skeletal 
muscle cells.   
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4.1.3. PAK1 signals to p41-ARC to mediate ARP2/3 complex 
formation 
On the other side of the actin remodeling cycle, the polymerization of actin was 
known to be regulated by the actin nucleating ARP2/3 complex in skeletal muscle 
cells [121]. My research extended this by identifying PAK1 as the upstream 
regulator of the ARP2/3 complex. A likely mechanism for this involves the PAK1-
mediated phosphorylation of p41-ARC, an infrequently used regulatory subunit of 
the ARP2/3 complex. Prior to my work, ARPC1 was not identified nor linked with 
PAK1 in any cell type other that in MCF-7 breast cancer cells [122]. My studies 
also went on downstream to incorporate a function for N-WASP. While N-WASP 
was implicated in skeletal muscle signaling, it’s activation and placement in the 
signaling cascade was unresolved. I was able to link this to PAK1 activity, using 
the pharmacological inhibitor of PAK1 (IPA3), which decreased the insulin-
stimulated association of N-WASP with p41-ARC and actin, indicating the 
requirement for PAK1 signaling in regulating the interactions between these three 
proteins. Demonstration of pPAK1 utilizing p41-ARC as a substrate, and the 
subsequent phosphorylation of p41-ARC in an insulin-stimulated and PAK1-
dependent manner remain to be confirmed in skeletal muscle cells. Moreover, 
PAK1 might also be involved in the regulation of microtubule dynamics to 
mediate GLUT4 vesicle translocation to the cell surface, by phosphorylating 
Ser65 and Ser128 of tubulin cofactor B (TCoB) [224]. This will need to be 
investigated, given that microtubules have been shown to be important for 
GLUT4 translocation and glucose uptake [204, 225]. Determining how PAK1 
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signaling interfaces with this process may uncover how GLUT4 vesicles transit 
across both networks to reach the cell surface. 
4.1.4. Does PAK1 indirectly regulate the activity of N-WASP, via a 
Rac1-feed-forward cycle? 
Another mechanism requires testing in skeletal muscle: that upon insulin 
stimulation, activated Rac1 binds to and activates PAK1, and PAK1 
phosphorylates Rho-GDI, the guanine dissociation inhibitor isoform that 
associates with Rac1, initiating a positive feed-forward mechanism [204]. 
Plausibility for this arises from studies showing that Rac1 binds to a CRIB 
domain present within N-WASP to facilitate N-WASP activation, initiating actin 
remodeling [218]. In other cell types, PAK1 can act upstream of Rac1 [189]. 
However, there is no evidence at present for this mechanism in skeletal muscle, 
and hence additional studies are needed to evaluate the possibility of a positive 
feed forward activation of Rac1 by PAK1 in these cells.  
4.2. FUTURE STUDIES  
4.2.1. Inducible muscle specific PAK1 KO mice  
Of the available skeletal muscle cell lines, the L6-GLUT4myc cell line is 
considered to be the most representative cell culture model of skeletal muscle 
function, enabling studies of the molecular mechanisms of skeletal muscle 
glucose metabolism in response to acute insulin signals. However, mature 
skeletal muscle differs from muscle cell culture models in their expression and 
reliance of various proteins involved in skeletal muscle glucose uptake. As such, 
studies using mouse models should be employed to validate the physiological 
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relevance of each protein and its network in vivo. While our lab and others have 
reported the whole body PAK1-/-KO mice as having impaired glucose tolerance 
and insulin resistance, there is controversy as to which tissues, skeletal muscle, 
pancreatic α or β cells, gut or brain, is the dominant cause of the phenotype. 
Hence further studies using an inducible skeletal muscle-specific PAK1 KO-/- 
mouse model will serve the purpose of determining the role and requirement for 
PAK1 in the maintenance of glucose homeostasis via regulating skeletal muscle 
GLUT4 mobilization and subsequent glucose uptake. To determine if the PAK1 
signaling network that my studies have unveiled is indeed conserved in the 
mature skeletal muscle glucose uptake process in vivo, the skeletal muscle from 
the inducible skm-PAK1 KO-/- mice should be analyzed for downstream signaling 
impairments of PAK1 (such as activation of Cofilin, ARP2/3 complex and N-
WASP). In addition, since each of the three group I PAK isoforms possess a 
similar tertiary structure, function and mode of activation, it would be interesting 
to see if there is any compensation from the other two group I PAKs (PAK2 and 
PAK3) in the absence of PAK1. Subsequent to the publication of my studies 
implicating PAK1 in these processes, Skm-Rac1-KO-/- mice were evaluated and 
shown to exhibit an insulin-resistant phenotype with defects in PAK1 activation 
(phosphorylation). Furthermore, PAK1 signaling impairments in skeletal muscle 
were associated with an insulin resistant phenotype both in murine models, and 
in human tissues from T2D subjects. Hence, it would be important to determine 
whether Rac1 levels are modulated in the absence of PAK1, as well as the 
alternative pathways that have been observed to occur in non-muscle cell types, 
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which might mediate a compensatory response to the loss of PAK1 in skeletal 
muscle. If inducible skm-PAK1-/-KO mice exhibit impaired glucose tolerance and 
insulin resistance, it would reiterate the importance of PAK1 in skeletal muscle 
glucose uptake and in the maintenance of whole body glucose homeostasis. 
However, it might also be possible that, the insulin resistant phenotype is instead 
due to the requirement for PAK1 in other tissues. In that case, if the inducible 
skm- PAK1-/-KO mice were found to have normal GLUT4 exocytosis, PAK1’s role 
in adipose-mediated glucose uptake in adipocytes should be evaluated, using 
adipocyte specific PAK1-/-KO mice. 
4.2.2. Muscle specific PAK1 overexpressing transgenic mice 
 PAK1 levels in T2D islets were ~80% reduced compared to levels present in 
their non-diabetic islets, implicating reduced PAK1 levels in diabetes. In contrast, 
PAK1 over-expression and hyper-activation has been associated with various 
types of cancers, with a large body of research focused upon inhibiting PAK1 as 
anti-cancer therapy [220]. These associations are correlative in nature however, 
with no side-by-side studies of a PAK1-overexpressing in vivo model compared 
with non- or hyper-activated PAK1 overexpressors. One report of cancer in a 
constitutively-active PAK1 overexpressing mouse model showed a more subtle 
phenotype than was expected or consistent with the correlative predictions 
derived from human tissue associations. Altogether, it can be presumed that anti-
cancer drugs aimed at inhibiting PAK1 might render cancer patients susceptible 
to peripheral insulin resistance, metabolic dysregulation and the development of 
T2D. Hence, muscle-specific PAK1 overexpressing mice would be a valuable 
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tool to determine the consequences of over expressing PAK1 in skeletal muscle, 
as well as to verify whether increasing PAK1 levels in the muscle could serve as 
a means to improve the insulin sensitivity. Moreover, use of an inducible muscle-
specific PAK1 overexpressing mouse model would permit the determination of 
whether PAK1 overexpression could protect against development of disease 
(induce the transgene prior to disease induction, e.g. via high-fat feeding, or 
crossing onto the db/db-BKS background) or could restore function to a diseased 
model (induce the transgene after the disease is developed).  
4.2.3. Novel PAK1 interacting partners 
PAK1 functions as a central node that mediates diverse functions of the cell by 
spatial-temporal regulation of its downstream effectors. PAK1 mediates the 
convergence of growth factor signaling and the adhesion signaling via activating 
the MAPK pathway by phosphorylating MEK1 on Ser298 [226]. Moreover, PAK1 
phosphorylates Raf1 at Ser338, which translocates to mitochondria and binds to 
Bcl-2 (anti-apoptotic protein) and exerts its pro-survival or anti-apoptotic function 
[227]. PAK1 regulates cell cycle progression by phosphorylating MEK1 (Ser298) 
and Raf1 (Ser338) of the MAPK pathway. Moreover, phosphorylation of paxillin 
on S273 by PAK stimulates the localization of the signaling complex including 
adaptor protein G-protein coupled receptor kinase-interacting protein 1 (GIT1), 
the Rac GEF PAK interactive exchange factor (PIX) and the activated PAK to the 
leading edge to regulate adhesion and protrusion dynamics. Adding to this with 
my research, PAK1 signaling to initiate F-actin remodeling in skeletal muscle 
cells leads to insulin-stimulated GLUT4 translocation. This multitude of signals 
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from PAK1 signaling to its downstream targets to execute various cellular 
functions suggests that any variation of PAK1 activity from normal will be 
deleterious to the cell. Hence, identification of novel interacting partners of PAK1 
which are specifically involved in the insulin-stimulated glucose uptake process, 
and not in the survival pathway, will provide us an opportunity to identify new 
potential therapeutic targets for T2D without affecting the normal survival/ anti-
apoptotic pathways. Toward this, a proteomics approach combining mass 
spectrometric analysis and co-immunoprecipitation of PAK1 can be used to 
identify novel PAK1 interacting partners. Analyzing L6-GLUT4myc cells and 
mature skeletal muscle from unstimulated and insulin-stimulated conditions will 
provide us with PAK1 interacting partners that are specific to insulin stimulation 
which might include scaffolding as well as signaling partners. Identified novel 
PAK1 interacting partners in the insulin signaling pathway can be validated for 
their role and function in insulin-stimulated glucose transport in skeletal muscle 
cells by knockdown or overexpression studies, and confirmed for their 
requirement in mature skeletal muscle. Finally, selected downstream targets of 
PAK1 specifically involved in insulin-induced GLUT4 mobilization can be tested 
for druggability as the novel therapeutic targets for treatment and/or prevention of 
insulin resistance and T2D. 
4.2.4. Correlation of PAK1 abundance and function with T2D 
susceptibility 
Obese and T2D patients, and several mouse models of insulin resistance or 
diabetes, show deficiencies in gastrocnemius and soleus skeletal muscle [176]. 
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PAK1 activation, cumulatively suggesting that dysregulated PAK1 signaling may 
be a significant contributor to the phenotype of peripheral insulin resistance, 
prediabetes and T2D. Therefore, diabetes-susceptible mouse models should be 
analyzed for PAK1 signaling impairments in the new proteins identified in the 
cascade in my studies, namely p41-ARC and Cortactin phosphorylations, and N-
WASP activation in skeletal muscle. Further, Single nucleotide polymorphism 
(SNP) of PAK1 gene in T2D patients compared to that of healthy individuals 
should be assessed to establish a correlation between PAK1 and T2D. Overall, 
these studies will aid in predicting the threshold of PAK1 protein levels or function 
in skeletal muscle, required to maintain normal insulin action and ways to restore 
PAK1 abundance/function in these tissues can later be exploited to maintain 
whole body glucose homeostasis.   
4.3. CONCLUSIONS 
 
Overall my above studies revealed that PAK1 functions downstream of Rac1 in 
an LIMK-independent manner in the process of insulin-stimulated glucose uptake 
in skeletal muscle cells. Ablation of PAK1 function resulted in abrogation of F-
actin remodeling dependent GLUT4 mobilization to the skeletal muscle cell 
surface in response to insulin. Interestingly, PAK1 regulates cofilin activity to 
induce insulin-dependent F-actin remodeling in a manner distinct from the other 
cell types, however the mechanism is yet to be determined. Moreover, PAK1’s 
role in the regulation of N-WASP-p41-ARC-actin complex to initiate cortical actin 
remodeling revealed a novel insulin signaling pathway that facilitates glucose 
uptake into skeletal muscle. Altogether, this study is significant because it is the 
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essential first step towards the development of pharmacologic strategies that will 
facilitate preservation of PAK1 function in skeletal muscle insulin action which are 
crucial to maintain glucose homeostasis. 
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